前往化源商城

113-38-2 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:AR protein [Homo sapiens]
External ID: MDAN535
Protocol: Please refer to other AIDs 743042 and 743041 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the AR antagonist mode assay (AID 743042) and cell viability counter screen (AID 743041). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryAR ActivityAR Potency (uM)AR Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0NCI
inconclusive agonistinconclusive agonistinactive0NCI
inconclusive antagonist (cytotoxic)active antagonist18.12455735-111.5015527active antagonist20.3992366-95.33077837NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)active antagonist33.49145963-71.97733202active antagonist33.49145963-45.59717193SigmaAldrich
inconclusive antagonist (cytotoxic)active antagonist24.63773286-89.63619394inconclusive antagonist33.49145963-42.65251674NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0active antagonist30.2961402-37.60775273NCI
inactiveinactive0inconclusive antagonistLabotest
active antagonistactive antagonist28.72548756-74.97879422inconclusive antagonist32.33061121-27.15821987NCI
active antagonistactive antagonist27.64399095-64.36631028inactive0NCI
inactiveinactive0inactive0NCI
inconclusive antagonist (cytotoxic)inconclusive antagonist33.49145963-64.79576401active antagonist32.7130197-37.67340069NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0NCI
inactiveinactive0inactive0Chembridge
inconclusive agonistinconclusive agonistinactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP3A4437
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (ketoconazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-8.32134.95490.64234-4.834640 0 0 0 0 0 1-4.4443-2.77887.36895.36932.33973.33831.6715-4.4443QC'd by Sytravon0
Inhibitor2.391969.704984Complete curve; high efficacy-5.62130.90.993-69.49290.212-1.10 0 0 0 0 0 0-66.6604-0.25131.2197-5.3806-9.9311-37.162-53.3921-66.6604QC'd by Sytravon0
Inhibitor9.522176.407442Partial curve; high efficacy-5.02131.1110.9951-75.90940.498-2.10 0 0 0 0 0 0-66.59123.4283-1.6815-1.5622-0.1199-13.7121-41.7015-66.5912QC'd by Sytravon0
Inactive0-4.52131.75290.9212-24.98775.540 0 0 0 0 0 0-17.48977.36232.46169.84163.36053.96510.8896-17.4897QC'd by Sytravon0
Inhibitor1.5092115.26487Complete curve; high efficacy-5.82131.46410.9934-109.85685.4073-1.10 0 0 0 0 0 0-110.2979-0.81499.86343.518-7.3368-73.6123-100.848-110.2979QC'd by Sytravon0
Inhibitor1.6933117.978187Complete curve; high efficacy-5.77134.50450.9912-112.735.2481-1.10 0 0 0 0 0 0-115.265815.93722.4103-1.24092.2518-88.9575-109.7932-115.2658QC'd by Sytravon0
Inhibitor4.772481.295643Partial curve; high efficacy-5.321310.9946-78.60572.6899-2.10 0 0 0 0 0 0-71.671-0.64476.43020.1885-3.4582-24.3313-55.7062-71.671QC'd by Sytravon0
Inhibitor7.563794.395183Complete curve; high efficacy-5.12134.95490.9967-94.6258-0.2307-1.10 0 0 0 0 0 0-93.87483.4317-2.5012-1.7201-2.44552.6182-85.3984-93.8748QC'd by Sytravon0
Inhibitor2.683765.029784Complete curve; high efficacy-5.57134.0950.989-65.3833-0.3537-1.10 0 0 0 0 0 0-70.4739-2.312-0.8042-1.22813.0628-22.6396-60.696-70.4739QC'd by Sytravon0
Inhibitor7.563757.206142Partial curve; partial efficacy-5.12131.62590.9942-54.13193.0742-2.20 0 0 0 0 0 0-52.30876.2072.82521.47620.0987-3.9796-35.0702-52.3087QC'd by Sytravon0
Inhibitor1.198874.619785Complete curve; high efficacy-5.92131.13410.9933-70.92043.6993-1.10 0 0 0 0 0 0-71.49064.2219-0.18864.5237-17.1469-46.9199-63.4145-71.4906QC'd by Sytravon0
Inhibitor2.1317118.451686Complete curve; high efficacy-5.67132.72020.993-110.08868.3631-1.10 0 0 0 0 0 0-116.12727.57825.10285.881412.5352-56.6231-102.2879-116.1272QC'd by Sytravon0
Inhibitor2.1317122.703187Complete curve; high efficacy-5.67132.40640.9787-115.72726.9759-1.10 0 0 0 0 0 0-122.07513.858917.443-6.083311.7009-62.2871-106.7609-122.0751QC'd by Sytravon0
Inhibitor6.7412121.082984Complete curve; high efficacy-5.17134.0950.9954-126.4671-5.3842-1.10 0 0 0 0 0 0-126.975-0.8069-3.4445-2.4548-11.8834-10.2564-113.7668-126.975QC'd by Sytravon0
Inhibitor4.772486.82744Partial curve; high efficacy-5.321310.9941-85.3831.444-2.10 0 0 0 0 0 0-78.6992-2.43161.8612-0.004-1.8987-28.5107-58.6303-78.6992QC'd by Sytravon0
Inhibitor7.5637125.15484Complete curve; high efficacy-5.12133.92950.9979-122.58722.5668-1.10 0 0 0 0 0 0-123.07953.09863.12671.8871-2.10935.2605-101.0355-123.0795QC'd by Sytravon0
Inhibitor0.6741119.919989Complete curve; high efficacy-6.17131.37230.9986-109.745410.1745-1.10 0 0 0 0 0 0-110.8548.84597.74156.7576-35.5397-88.9969-106.7803-110.854QC'd by Sytravon0
Inhibitor6.7412115.981384Complete curve; high efficacy-5.17132.30310.9963-113.59672.3846-1.10 0 0 0 0 0 0-113.37-1.2322-1.59845.85995.7708-6.0722-86.9448-113.37QC'd by Sytravon0
Inhibitor1.5092114.050988Complete curve; high efficacy-5.82131.96730.9946-113.91580.1351-1.10 0 0 0 0 0 0-113.0117-0.8223-4.0553-2.3728-1.6822-81.3904-111.2484-113.0117QC'd by Sytravon0
Inhibitor8.486660.792742Partial curve; partial efficacy-5.07132.40640.9868-57.96392.8287-2.20 0 0 0 0 0 0-56.54736.87814.87661.3348-2.20081.3516-39.1581-56.5473QC'd by Sytravon0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1100
Protocol: DT40-hTDP1 cells without 20 nM Camptothecin (add 20 microL of DMSO in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inactive04-3.0662-2.41261.9741-4.0617-0.6298-3.0662QC'd by "Chem Div"
Inactive04.95490.7346-0.808-4.30840 0 0 0 0-0.431-4.3080.8987-1.5892-1.522-0.431QC'd by "Chem Div"
Inactive04.95490.6448-12.51274.558540 0 0 0 0-9.75096.55851.6006-0.810411.697-9.7509QC'd by "Chem Div"
Inhibitor18.356499.037841Partial curve; high efficacy-4.73622.84730.9985-99.5803-0.5425-2.10 0 0 0 0-92.8278-1.5772-1.93651.8258-13.1847-92.8278QC'd by "Chem Div"
Inhibitor29.092942.181510Single point of activity-4.53624.95490.9879-50.8391-8.6577-30 0 0 0 0-46.8496-7.6387-8.6142-11.6103-6.66-46.8496QC'd by "Chem Div"
Inhibitor18.3564123.871841Partial curve; high efficacy-4.73621.62590.9975-121.45782.414-2.10 0 0 0 0-98.82245.0098-1.1767-0.5372-27.2941-98.8224QC'd by "Chem Div"
Inhibitor14.581109.907342Partial curve; high efficacy-4.83621.82650.9637-106.40863.4987-2.10 0 0 0 0-94.670912.0352-9.70946.0901-28.9742-94.6709QC'd by "Chem Div"
Inactive00.30.9096-34.0578-3.769740 0 0 0 0-28.0098-7.7697-15.2699-21.1534-19.3019-28.0098QC'd by "Chem Div"
Inhibitor29.092990.897810Single point of activity-4.53624.44950.9936-90.33680.561-30 0 0 0 0-79.96355.0637-2.1732-1.69030.5114-79.9635QC'd by "Chem Div"
Inactive00.30.426615.2787-6.721340 0 0 0 010.4803-5.72138.5589-5.30466.71910.4803QC'd by "Chem Div"
Inactive01.96730.6089-9.50825.296840 0 0 0 0-7.95747.2968-1.890310.39461.3036-7.9574QC'd by "Chem Div"
Inhibitor16.360145.504710Single point of activity-4.78624.95490.9618-49.1256-3.6209-30 0 0 0 0-48.9315-7.5358-6.3332.7698-6.0371-48.9315QC'd by "Chem Div"
Inactive0-5.28620.80.9747-26.74278.437240 0 0 0 0-20.71279.43722.29650.248-14.6534-20.7127QC'd by "Chem Div"
Inactive04.95490.9526-10.392812.159440 0 0 0 0-10.30087.659413.806714.3816-9.7278-10.3008QC'd by "Chem Div"
Inactive02.25260.9456-15.0824-3.824740 0 0 0 0-14.7061-2.8247-5.6912-3.1226-9.4063-14.7061QC'd by "Chem Div"
Inhibitor12.995378.844742Partial curve; high efficacy-4.88621.55790.9935-82.5518-3.7072-2.10 0 0 0 0-72.8175-6.4603-0.3489-8.7793-32.8366-72.8175QC'd by "Chem Div"
Inhibitor18.356449.742410Single point of activity-4.73622.84730.9797-46.14163.6008-30 0 0 0 0-42.7679-0.89924.9836.9739-2.5062-42.7679QC'd by "Chem Div"
Inactive04.95490.8308-9.79910.472540 0 0 0 0-5.08718.47258.256110.070916.081-5.0871QC'd by "Chem Div"
Inactive01.88510.9722-5.76856.220540 0 0 0 0-5.0636.2205-1.5445-7.1037-5.5678-5.063QC'd by "Chem Div"
Inactive00.30.842-31.92493.17440 0 0 0 0-26.7418-0.826-13.6909-13.1344-14.0869-26.7418QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2D6395
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (quinidine) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at room temperature for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0-7.260.70.983122040 0 0 0 0 0 0 018.72430.75090.74030.16150.22082.57129.062412.490518.7243QC'd by Labotest0
Inactive00043.08132.90954.18193.06831.54751.9993-1.48293.82823.0813QC'd by Labotest0
Inhibitor10.96462.697110Partial curve; high efficacy; poor fit-4.964.95490.998-66.9977-4.3007-2.31 0 0 0 0 0 0 0-65.7875-42.8846-3.6636-4.8429-3.3836-3.8623-4.4736-41.4229-65.7875QC'd by Microsource0
Inhibitor38.901833.850110Partial curve; partial efficacy; poor fit-4.414.95490.924-33.35010.5-2.40 0 0 0 0 0 0 0-29.0418-1.55510.52060.875-1.2476-0.5605-1.80927.4199-29.0418QC'd by SIGMA0
Inhibitor1.737781.229885Complete curve; high efficacy-5.761.96730.9976-79.95641.2734-1.10 0 0 0 0 0 0 0-78.3324.47950.76060.0181-0.701-3.7995-49.0322-80.0522-78.332QC'd by Tocris0
Inhibitor34.671337.231710Partial curve; partial efficacy; poor fit-4.462.35310.9195-37.23170-2.40 0 0 0 0 0 0 0-28.52643.96925.0423-3.0201-3.1048-1.1738-0.8348-2.4447-28.5264QC'd by Microsource0
Inhibitor15.487171.27341Partial curve; high efficacy-4.811.44870.9928-70.41130.8617-2.10 0 0 0 0 0 0 0-61.76430.28531.9381-1.2811-0.34364.6186-4.2001-27.4432-61.7643QC'd by GVK0
Inhibitor0.218891.972890Complete curve; high efficacy-6.660.80.9894-90.01021.9626-1.10 0 0 0 0 0 0 0-83.87692.77070.8657-14.6874-27.4321-55.0254-79.0233-92.6031-83.8769QC'd by Prestwick Chemical; Inc.0
Inhibitor34.671345.828810Single point of activity-4.462.35310.9938-45.82880-30 0 0 0 0 0 0 0-35.0976-0.4182-0.112-0.91482.1786-0.5211-0.77-3.3082-35.0976QC'd by Vitas0
Inhibitor13.8029116.598142Partial curve; high efficacy-4.860.70.9704-115.4741.1242-2.10 0 0 0 0 0 0 0-87.4803-1.2071.2781-1.1552-1.0641-0.761-34.877-47.6739-87.4803QC'd by Vitas0
Inhibitor19.497171.169541Partial curve; high efficacy-4.712.33320.9649-71.6292-0.4597-2.10 0 0 0 0 0 0 0-66.007-7.5073.5896-6.58233.21022.04942.4442-17.4355-66.007QC'd by Enzo0
Inactive0004-0.33970.68341.1935-3.1601-7.1353-6.692-3.5353-4.6055-0.3397QC'd by Microsource0
Inhibitor38.901899.707710Single point of activity-4.412.90230.9979-103.2475-3.5398-30 0 0 0 0 0 0 0-78.9754-2.6538-1.9475-2.4198-3.036-5.7354-4.4174-6.1242-78.9754QC'd by Labotest0
Inactive00040.55794.29663.86970.9141.57842.77632.2827-0.27460.5579QC'd by Microsource0
Inactive0004-2.28934.50485.93892.79056.12561.13645.75735.7586-2.2893QC'd by Tocris0
Inhibitor12.301842.282721Partial curve; partial efficacy-4.912.33320.9667-45.1528-2.8702-2.20 0 0 0 0 0 0 0-43.5551-8.1379-5.4062-0.92150.1464-0.2747-3.1761-22.7908-43.5551QC'd by Labotest0
Inactive00042.7074-0.37290.3242.07662.64641.1615-0.70884.47812.7074QC'd by Prestwick0
Inactive0004-1.99643.70481.65273.62083.19225.03624.9342-1.7586-1.9964QC'd by Microsource0
Inactive0-6.360.80.89615-7.047740 0 0 0 0 0 0 04.9227-4.8515-7.6164-8.7898-3.26990.29170.34185.50584.9227QC'd by VitasInactive00
Inhibitor3.4671109.162545Partial curve; high efficacy-5.460.90.9982-103.53135.6312-2.10 0 0 0 0 0 0 0-96.39795.98693.1773.47834.7559-9.3266-39.4946-74.1667-96.3979QC'd by Enzo0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1101
Protocol: DT40-hTDP1 cells with 20 nM Camptothecin (add 20 microL of 1 mM CPT stock in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inhibitor20.5962118.89141Partial curve; high efficacy-4.68622.30310.9994-116.16692.7241-2.10 0 0 0 0-99.94512.72414.25720.7717-13.7373-99.9451QC'd by "Asinex Ltd."
Inactive00.80.9749-16.17712.005740 0 0 0 0-13.14662.00571.2486-2.8352-5.7162-13.1466QC'd by "Asinex Ltd."
Inactive04.95490.6148-11.8012.205940 0 0 0 0-9.7999-4.79413.64526.73633.1419-9.7999QC'd by "Asinex Ltd."
Inactive0-5.03622.33320.9795-28.8852-5.272340 0 0 0 0-28.1997-7.2723-3.3531-4.7215-17.5124-28.1997QC'd by "Asinex Ltd."
Inhibitor5.173594.688584Complete curve; high efficacy-5.28622.90230.9917-96.1842-1.4957-1.10 0 0 0 0-96.0073-7.53084.5779-6.8491-81.1577-96.0073QC'd by "Asinex Ltd."
Inhibitor18.356494.01210Single point of activity-4.73623.62720.9999-96.5346-2.5226-30 0 0 0 0-93.107-2.9055-1.9361-2.363-9.7613-93.107QC'd by "Asinex Ltd."
Inactive04.95490.8434-31.3086-2.25540 0 0 0 0-27.0497-0.755-10.5210.92280.8125-27.0497QC'd by "Asinex Ltd."
Inactive04.44950.7303-25.728-7.249240 0 0 0 0-25.3982-8.7492-13.51280.9177-19.0413-25.3982QC'd by "Asinex Ltd."
Inhibitor20.5962100.541141Partial curve; high efficacy-4.68622.09370.998-104.3872-3.8461-2.10 0 0 0 0-88.9539-4.1551-2.0443-7.1093-18.8654-88.9539QC'd by "Asinex Ltd."
Inhibitor29.092991.413310Single point of activity-4.53624.95490.9947-88.35973.0536-30 0 0 0 0-79.845-1.16852.65594.53855.7131-79.845QC'd by "Asinex Ltd."
Inactive04.95490.786-1.849912.995440 0 0 0 116.19477.995418.22950.5262-1.875716.1947QC'd by "Asinex Ltd."
Inactive04.95490.9259-4.54544.383940 0 0 0 0-3.72395.38394.7472.6664.8335-3.7239QC'd by "Asinex Ltd."
Inactive0-6.23624.95490.9762-1.408619.454340 0 0 0 01.208619.454317.7088-3.3481-2.37561.2086QC'd by "Asinex Ltd."
Inactive04.95490.4363-4.5616-11.561640 0 0 0 0-4.5336-11.5616-1.6565-10.5162-2.2482-4.5336QC'd by "Asinex Ltd."
Inactive00.70.98896.5184-6.981640 0 0 0 02.8921-7.4816-5.7762-3.9537-1.52422.8921QC'd by "Asinex Ltd."
Inactive04.95490.5926-22.1394-0.155940 0 0 0 0-20.8088-4.1559-8.30412.2914-0.0696-20.8088QC'd by "Asinex Ltd."
Inhibitor29.092964.218610Single point of activity-4.53624.95490.9684-70.1227-5.9041-30 0 0 0 0-64.396-9.2052-0.418-11.9994-2.9068-64.396QC'd by "Asinex Ltd."
Inactive01.210.9644-26.92634.843740 0 0 0 0-17.96476.84374.96630.5719-1.9517-17.9647QC'd by "Asinex Ltd."
Inactive04.95490.9261-29.9871.936440 0 0 0 0-26.99980.4364-0.7582-0.45327.9656-26.9998QC'd by "Asinex Ltd."
Inactive04.0950.45761.780312.60740 0 0 0 06.613211.107-4.99860.1865.25796.6132QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: MDAV150
Protocol: Tox21 Assay Protocol Summary:

MDA-kb2 AR-luc cells were dispensed at 3,000 cells/4 uL/well of culture medium into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37C and 0% CO2 for 5 hr, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of agonist (R1881) in culture medium using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at a 37C and 0% CO2 for 16 h. After 15.5 h incubation, 1uL of CellTiter-Fluor reagent (Promega) was added using a Bioraptr FRD to each plate for measuring cytotoxicity. The fluorescence intensity was quantified on a ViewLux plate reader (PerkinElmer, Shelton, CT) following 30 min incubation at 37C and 0% CO2.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002746821 uM-Replicate_1Activity at 0.0005960927 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.761 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.16 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.95 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive043.9341-4.0025-4.45586.8198-1.1644-4.92122.01380.18830.932-6.078-2.34493.01673.4002-5.54413.9341QC'd by NCIInactive04.50450.56978
Cytotoxic15.6421110.147982Complete curve; high efficacy-4.80572.72020.9603-107.6072.5408-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0-95.90644.73640.534-1.15171.49885.7269-3.13844.6023-2.5915.101-0.7039-0.1448-2.8091-85.7578-95.9064QC'd by NCICytotoxic26.603280.513740Partial curve; high efficacy-4.57513.1320.9819-78.1328
Inactive00.30.5018-6.6712640 0 0 0 0 0 0 0 0 0 0 0 0 0-4.483807.84125.0947-0.36850.9766-4.3547-0.66533.21310-2.6766-3.7672-6.3927-2.7561-4.4838QC'd by NCIInactive0
Cytotoxic33.491553.023520Single point of activity-4.47514.95490.9093-57.314-4.2905-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-50.2755-6.13-5.7216-6.0909-1.1322-4.0113-6.953-0.8667-0.5352-3.8081-2.7523-6.4736-0.2391-14.0348-4.1839-50.2755QC'd by SigmaAldrichCytotoxic33.491543.216120Single point of activity-4.47514.95490.9489-44.7217
Inactive03.06540.64480.20834.321840 0 0 0 0 0 0 0 0 0 0 0 0 0-18.894333.038234.043-6.70165.11124.24770.05467.51211.52441.08954.9424.91169.6713-8.8416-18.8943QC'd by NCICytotoxic33.491538.402820Single point of activity-4.47514.95490.832-38.6215
Inactive04.95490.7541-3.03628.540 0 0 0 0 0 0 0 0 0 0 0 0 0-1.65425.818611.123-2.6648-5.527-2.1108-0.7834-0.2795-1.3292-6.2801-5.9904-3.6693-1.3675-3.1321-1.6542QC'd by NCIInactive04.95490.3332-0.5
Inactive04.95490.84961.39232240 0 0 0 0 0 0 0 0 0 0 0 0 04.046617.94353.1030.41822.1955-0.17152.82353.96390.0788-0.239-2.58983.38281.79160.39744.0466QC'd by NCIInactive04.50450.9224-0.7305
Inactive03.51170.39273-1.695140 0 0 0 0 0 0 0 0 0 0 0 0 0 02.3532-0.7162-0.0074-1.51420.6742-1.9219-3.891-3.1053-2.3524-2.8619-0.949-1.1980.6682-4.74592.1422.3532QC'd by NCIInactive0
Cytotoxic31.2143.456620Single point of activity-4.50574.95490.7461-46.3321-2.8755-30 0 0 0 0 0 0 0 0 0 0 0 0 0-45.4236-23.2298-4.49953.3316-2.32112.1332-2.31951.5412-1.1787-5.146-0.56271.3154-5.0727-6.7293-45.4236QC'd by NCICytotoxic26.603238.826420Partial curve; partial efficacy-4.57513.1320.8519-40.8264
Cytotoxic26.603234.702920Partial curve; partial efficacy-4.57512.40640.9771-38.2666-3.5637-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.0555-4.6672-2.5088-5.4716-4.3602-4.1809-2.6891-4.1367-1.8067-1.3031-4.0865-2.8527-4.2279-4.8434-16.0218-31.0555QC'd by LabotestInactive03.06540.7575-18.2037
Cytotoxic31.2126.94420Partial curve; partial efficacy; poor fit-4.50574.95490.8037-24.9442-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0-24.1210.59991.3585-0.3563-0.60562.1079-1.54786.16642.4623-1.89281.97841.18620.52481.7585-24.12QC'd by NCICytotoxic33.491527.372520Partial curve; partial efficacy; poor fit-4.47514.95490.8005-26.3725
Inactive01.62660.7987-19.85024.540 0 0 0 0 0 0 0 0 0 0 0 0 0-14.87519.4894-1.33438.71942.60745.36513.28525.9036.96833.64690.0211-0.04561.4841-14.2523-14.8751QC'd by NCIInactive0
Inactive047.36137.5196-7.3951-0.70231.14315.96320.48820.14911.02055.83171.3822-0.343410.53266.96547.3613QC'd by NCIInactive0
Cytotoxic31.2131.422720Single point of activity-4.50574.95490.8431-33.9227-2.5-30 0 0 0 0 0 0 0 0 0 0 0 0 0-33.2689-9.9006-5.5288-1.4219-0.0243-6.7803-3.4216-2.11071.4914-3.4573-1.8023-3.3297-0.1019-0.8542-33.2689QC'd by NCICytotoxic33.491551.227920Single point of activity-4.47514.95490.8738-54.2347
Inactive048.1128-3.52191.60923.5704-3.05675.54251.1281.79473.9211.45843.09545.7098-1.1492.90538.1128QC'd by NCIInactive0
Inactive04.95490.54013-7.823740 0 0 0 0 0 0 0 0 0 0 0 0 01.1178-1.9427-14.01981.42342.61488.01592.12438.1348-0.05886.06141.26242.49191.59630.22081.1178QC'd by NCIInactive0
Inactive043.42253.6223-3.44319.3218-0.1732-0.80331.8093-2.39193.81192.1766-1.5835-1.20313.85931.62713.4225QC'd by NCIInactive04.95490.38771
Inactive04.95490.42743.5-1.818940 0 0 0 0 0 0 0 0 0 0 0 0 0 04.6673-1.0353-6.09910.1105-0.7736-1.0905-3.54160.56970.18692.2758-5.4321-2.2238-3.56285.220.99214.6673QC'd by ChembridgeInactive0
Cytotoxic27.815930.261720Partial curve; partial efficacy; poor fit-4.55574.95490.7703-27.76172.5-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0-26.4681-2.20990.61468.7045-3.0357-3.4205-0.0515-0.023510.83455.83643.293.32762.2442-2.1893-26.4681QC'd by NCIInactive04.95490.7812-21.5734
Inactive04-7.12970.2395-3.92457.56442.93285.83127.2431-2.9052-0.36468.84164.56552.17381.58961.9706-7.1297QC'd by NCIInactive04.50450.5518-8.9683
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: CYP2C9536
Protocol: Assay Protocol Summary:

Two ul of enzyme-substrate mix supplemented with 0.4% Bovine Serum Albumin was dispensed into medium binding white/solid 1536-well plates (Greiner Bio-One North America Inc., Monroe, NC) using a Flying Reagent Dispenser (FRD, Aurora Discovery, San Diego, CA). Test compounds dissolved in DMSO and positive control (sulfaphenazole) were transferred to the assay plates at 23 nl using a Pintool station (Wako, San Diego, CA). The assay plates were incubated at room temperature for 10 min. Then 2 ul of NADPH regeneration solution was added to each well of the assay plates using an FRD and incubated at 37C for 1 h. The reaction was stopped by adding 4 ul of detection reagent using an FRD and after 20 min incubation at room temperature, the luminescence signal was measured using a ViewLux plate reader (Perkin Elmer, Shelton, CT). Data were expressed as relative luminescence units.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000073560 uM-Replicate_1Activity at 0.0000367800 uM-Replicate_1Activity at 0.0000735600 uM-Replicate_1Activity at 0.0001677464 uM-Replicate_1Activity at 0.0003678000 uM-Replicate_1Activity at 0.0007362988 uM-Replicate_1Activity at 0.00153 uM-Replicate_1Activity at 0.00368 uM-Replicate_1Activity at 0.00723 uM-Replicate_1Activity at 0.00914 uM-Replicate_1Activity at 0.018 uM-Replicate_1Activity at 0.039 uM-Replicate_1Activity at 0.092 uM-Replicate_1Activity at 0.191 uM-Replicate_1Activity at 0.460 uM-Replicate_1Activity at 0.910 uM-Replicate_1Activity at 1.182 uM-Replicate_1Activity at 2.302 uM-Replicate_1Activity at 4.834 uM-Replicate_1Activity at 11.49 uM-Replicate_1Activity at 23.94 uM-Replicate_1Activity at 57.45 uM-Replicate_1Activity at 115.4 uM-Replicate_1Activity at 193.5 uM-Replicate_1Activity at 288.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inhibitor21.317485.520741Partial curve; high efficacy-4.67133.19250.957-74.520711-2.10 0 0 0 0 0 0-71.26736.65818.66165.03429.029624.68310.5948-71.2673QC'd by Microsource0
Inactive00040.31867.0625.1975.69257.23591.2670.52010.3186QC'd by Microsource0
Inhibitor7.563793.544743Partial curve; high efficacy-5.12131.92820.9984-89.27954.2653-2.10 0 0 0 0 0 0-87.52897.16565.07882.79792.1575-3.7741-60.4613-87.5289QC'd by Tocris0
Inhibitor26.83748.635610Single point of activity-4.57132.24810.9788-42.84845.7872-30 0 0 0 0 0 0-35.46775.96295.47962.709210.27554.6543-0.1967-35.4677QC'd by NCI0
Inhibitor8.4866130.766843Partial curve; high efficacy-5.071310.9992-119.896710.8701-2.10 0 0 0 0 0 0-102.475811.946611.24277.15545.0781-16.0537-65.0649-102.4758QC'd by BIOMOL0
Inhibitor5.354799.189644Partial curve; high efficacy-5.27130.90.9888-96.57122.6185-2.10 0 0 0 0 0 0-87.001-0.2592-1.6376.8143-4.5159-32.2161-61.4841-87.001QC'd by BIOMOL0
Inactive0-4.67132.33320.6923-15.1448-0.540 0 0 0 0 0 0-13.8707-3.7401-1.27785.1005-4.69041.916-3.5213-13.8707QC'd by InterBioScreen0
Inhibitor25.401256.202240Partial curve; partial efficacy-4.59514.50450.9727-57.7888-1.5865-2.20 0 0 0 0 0 0 0-57.6748-1.4876-4.4957-6.22962.86763.1906-3.7494-18.0858-57.6748QC'd by LightBiologicalsInhibitor40.258241.12110Single point of activity-4.39512.95230.943-42.7254
Inhibitor7.563797.471243Partial curve; high efficacy-5.12131.92820.9955-91.45176.0195-2.10 0 0 0 0 0 0-89.13426.42811.19024.98681.8065-2.3315-62.2028-89.1342QC'd by Tocris0
Inhibitor21.317476.663841Partial curve; partial efficacy-4.67131.24750.9713-70.16386.5-2.20 0 0 0 0 0 0-53.059711.862810.1962-0.30794.2931.9517-17.9254-53.0597QC'd by SigmaAldrich0
Inhibitor26.837101.665640Partial curve; high efficacy-4.57131.59360.9916-96.27045.3952-2.10 0 0 0 0 0 0-73.31095.62388.78586.24482.4666-0.9326-13.5438-73.3109QC'd by Tocris0
Inhibitor3.790887.146544Partial curve; high efficacy-5.42130.80.9942-85.19521.9512-2.10 0 0 0 0 0 0-78.88451.4625-1.87161.6032-10.9203-35.4628-58.552-78.8845QC'd by Tocris0
Inhibitor37.9083129.914810Single point of activity-4.42134.95490.9896-129.29750.6173-30 0 0 0 0 0 0-114.6255-1.4437-2.5082-0.90198.8381-4.54583.1106-114.6255QC'd by SigmaAldrich0
Inhibitor26.837109.062140Partial curve; high efficacy-4.57131.34370.9459-109.3538-0.2917-2.10 0 0 0 0 0 0-82.84382.53255.07320.78280.5149-19.3744-20.4297-82.8438QC'd by Bosche0
Inactive0-4.412.90230.8395-17.3952-0.540 0 0 0 0 0 0 0-13.246-3.84691.9539-0.2562-2.65371.4770.7446-0.9487-13.246QC'd by ACC0
Inactive0-8.363.1320.36283-4.516440 0 0 0 0 0 0 02.109-4.1803-1.83775.2557-1.05048.3001-3.10856.7452.109QC'd by Pharmaron0
Inactive00040.5041-8.57852.70450.1138-10.58420.93582.08840.5041QC'd by Toronto Research0
Inhibitor44.493235.276510Single point of activity-4.35173.67720.8478-34.72730.5492-30 0 0 0 0 0 0 0-32.3137-1.4989-3.7044-1.139-0.492412.1946-1.1884-3.139-32.3137QC'd by RTI0
Inactive00046.63087.63316.0247.39860.22633.18743.42856.6308QC'd by Tocris0
Inactive00045.326112.576410.112211.536311.2627.1953.95915.3261QC'd by NCGCChem0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:RecName: Full=ATPase family AAA domain-containing protein 5; AltName: Full=Chromosome fragility-associated gene 1 protein
External ID: ELG271
Protocol: Please refer to other AIDs 651632 and 651634 for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the ATAD5 assay (AID 651632) and cell viability counter screen (AID 651634). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryATAD5 ActivityATAD5 Potency (uM)ATAD5 Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
active agonistactive agonist19.3311819612.17977568inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0TCI
inactiveinactive0inactive0Alfa Aesar
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inconclusive antagonistinconclusive antagonist-22.16843258active antagonist30.63785869-80.36907549SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
inactiveinactive0inactive0SIGMA
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:24386 靶标:N/A
External ID: Sarm1 Tir NADase inhibitors screen
Protocol: NRK1-HEK293T cells were seeded onto 150 cm2 plates at 20 x 106 cells per plate. The next day, the cells were transfected with 15 microg FCIV-SST (SAM-TIR expression plasmid) using X-tremeGENE 9 DNA Transfection Reagent (Roche product #06365787001). The cultures were supplemented with 1 mM nicotinamide riboside at time of transfection to minimize toxicity from SAM-TIR overexpression. Forty-eight hours after transfection, cells were harvested, pelleted by centrifugation at 1,000 rpm (Sorvall ST 16R centrifuge, Thermo Fisher), and washed once with cold PBS (0.01 M phosphate buffered saline NaCl 0.138 M; KCl 0.0027 M; pH 7.4). The cells were resuspended in PBS with protease inhibitors (Complete protease inhibitor cocktail, Roche product # 11873580001) and cell lysates were prepared by sonication (Branson Sonifer 450, output = 3, 20 episodes of stroke). The lysates were centrifuged (12,000xg for 10 min at 4 degrees C) to remove cell debris and the supernatants (containing SARM1 SAM-TIR protein) were stored at -80 degrees C for later use in the in vitro SARM1 SAM-TIR NADase assay (see below). Protein concentration was determined by the Bicinchoninic (BCA) method.

This screen is an adaptation of the NAD/NADH Glo assay (Promega G9071). In this assay, NAD cycling enzymes convert NAD into NADH. In the presence of NADH, the reductase enzymatically converts a proluciferin reductase substrate into luciferin. Luciferin is detected using Ultra-GloTM rLuciferase, and the chemiluminescence intensity is proportional to the amount of NAD and NADH in the sample. In our diluted lysate alone, the amount of NAD and NADH is undetectable with this assay precluding any endogenous contribution to the final NAD detected. The assay was set up as follows: 2 microl candidate inhibitor (final concentration 1 microM, 2% DMSO), 0.07 microg lysate (2 microl), and 2 microl of 400 nM NAD. The reaction was incubated at 37 degrees C for 60 min, then 6 microl NAD/NADH Glo detection reagent was added. After 30 min at room temperature, the luminescent signals were quantified using a Cytation5 imaging reader (BioTek). The SARM1 SAM-TIR lysate catalyzed a dose-dependent depletion of NAD, whereas NAD levels did not decline when reactions were performed with lysate prepared from control NRK1-HEK293T cells.
Comment:
NAD(nM)
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
10
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:thyroid hormone receptor beta isoform 2 [Rattus norvegicus]
External ID: TRN186
Protocol: Tox21 Assay Protocol Summary:

GH3.TRE-Luc cells were dispensed at 1500 cells/4 uL/well into 1536-well white solid bottom plates using a Multidrop Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37 C for 4 hours, 23 nL of library compound or DMSO controls was transferred to the assay plates by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 ul of T3 (1 nM, final concentration in the wells) to stimulate TR transactivation. The assay plates were incubated at 37 C for 23.5 h, and then 1 uL of CellTiter-Fluor reagent (Promega, Madision, WI) of measuring cytotoxicity was added to each well using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at 37 C and 5% CO2 for additional 30 min, and fluorescence intensity was measured by a ViewLux plate reader (PerkinElmer, Shelton, CT). For measuring luciferase reporter gene activity, 4 uL of ONE-Glo Luciferase Assay reagent (Promega) was added to each well using a Bioraptr FRD (Beckman Coulter), followed by 30 min incubation at room temperature. The luminescence intensity of plates was recorded by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001392246 uM-Replicate_1Activity at 0.0002720894 uM-Replicate_1Activity at 0.0005955118 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.762 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.793 uM-Replicate_1Activity at 8.439 uM-Replicate_1Activity at 18.15 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.0950.3471-11.4032.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.50250.1158-3.1697-0.33515.6720.861714.90173.38536.9176-0.23470.4322-0.26143.98420.0305-0.2471-9.5025QC'd by NCIInactive0
Inhibitor8.4127111.383Complete curve; high efficacy-5.07514.50450.9828-108.24563.0545-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-112.7558-1.15723.06639.00343.54455.92481.74539.42291.34811.146-12.38566.95031.0946-61.7744-103.2834-112.7558QC'd by NCIInhibitor11.8832114.52442Partial curve; high efficacy-4.92512.95230.9725-113.8942
Inhibitor33.4915108.428710Single point of activity-4.47514.95490.9805-106.41752.0112-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.3487-0.0130.29265.8092.3543-1.529-1.86081.7268-1.32142.07110.45466.4268-1.17365.0616-1.2831-93.3487QC'd by NCIInhibitor33.491545.255310Single point of activity-4.47514.95490.8805-44.8499
Inhibitor6.6824112.359884Complete curve; high efficacy-5.17512.72020.9976-112.35980-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-107.86851.8367-0.98520.055-0.0873-0.0192-0.22741.70630.4571-0.0314-1.0907-6.2723-21.2839-82.4952-110.1566-107.8685QC'd by SigmaAldrichInhibitor11.8832118.081443Partial curve; high efficacy-4.92511.80790.9544-118.7095
Inhibitor6.6824105.669684Complete curve; high efficacy-5.17514.95490.9938-106.8079-1.1383-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-105.07267.23320.2468-0.2504-1.5237-2.6002-3.7474-7.12-3.24092.46950.0289-2.5534-12.3799-89.7924-106.5947-105.0726QC'd by NCIInhibitor9.4392121.220283Complete curve; high efficacy-5.02513.990.9879-117.3663
Inactive01.39870.58200.743840 0 0 0 0 0 0 0 0 0 0 0 0 0 16.5615-1.2435-1.42584.69634.22561.3627-6.880211.4156-5.29793.471-0.63623.942610.207711.431217.98796.5615QC'd by NCIInactive04.95490.50497
Inactive048.6584-0.25360.6070.1862-7.14463.14683.8879-0.6670.72263.43975.19140.62353.6739-0.02550.89198.6584QC'd by NCIInactive00.80.38469
Inactive0410.54210.43950.42364.47171.1049-1.458613.91965.5002-1.05963.065-7.07060.06181.202510.164811.16310.5421QC'd by NCIInactive03.990.606418
Inactive04-2.79550.91070.63340.0441-1.57746.62466.8752-6.6198-1.914714.01640.09133.5513.40912.4192-0.0362-2.7955QC'd by NCIInactive01.82650.72117
Inhibitor29.849398.496140Partial curve; high efficacy-4.52512.58840.9136-98.06750.4287-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-74.29356.770611.4199-0.0327-7.65161.0084-7.6141-0.0057-4.1882-0.0137-5.30869.05936.513-11.2634-24.6953-74.2935QC'd by LabotestInhibitor23.710181.201341Partial curve; high efficacy-4.62511.62660.9814-85.328
Inhibitor11.8832113.855282Complete curve; high efficacy-4.92513.51170.9826-115.6541-1.7989-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-108.9022-2.57351.71220.0161-0.9518-6.581711.0269-0.7611-7.71670.0417-2.5311-7.3404-6.9128-34.9326-107.0686-108.9022QC'd by NCIInhibitor13.3332117.674582Complete curve; high efficacy-4.87513.1320.9752-119.5106
Inhibitor11.8832100.560342Partial curve; high efficacy-4.92512.30310.9844-98.40762.1527-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.4781-3.68021.45591.078-0.28983.594211.15550.03471.61545.5371-0.609-0.03380.0197-37.731-72.8614-96.4781QC'd by NCIInhibitor11.8832104.835482Complete curve; high efficacy-4.92512.84730.9729-101.2413
Inactive049.109716.353612.83932.63922.84184.686310.95966.499811.73249.79221.807413.675211.786911.24189.60329.1097QC'd by NCIInactive04.95490.571320.5
Inhibitor9.4392111.014483Complete curve; high efficacy-5.02513.06540.9851-108.05722.9572-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-104.01842.36323.22810.98985.081712.35020.2029-2.0107-1.81368.62391.97771.5258-9.3399-43.8626-105.9384-104.0184QC'd by NCIInhibitor11.8832117.796983Complete curve; high efficacy-4.92513.51170.9855-119.6341
Inactive01.10.49998.50.760140 0 0 0 0 0 0 0 0 0 0 0 0 0 06.7333-1.17177.005-0.40612.2711-1.86660.092310.02274.12186.31389.59344.80676.54059.438813.04816.7333QC'd by NCIInactive03.51170.516322
Inhibitor23.710130.537110Partial curve; partial efficacy; poor fit-4.62514.44950.7197-30.53710-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-29.1975-0.68221.0324-2.45350.1458-0.1477-0.2161-13.6864-3.44241.79450.06561.3783.68649.5588-10.7074-29.1975QC'd by NCIInactive04.95490.9007-21.9629
Inactive0413.5114-0.54170.0115-0.029211.3153-0.00342.57815.33694.0109-1.29990.1952.6113-0.1351-0.43365.290313.5114QC'd by NCIInactive00.80.552326
Inactive040.5778-0.8927-0.3832-2.6058-1.17790.83535.6138-2.89484.8776-1.355-0.2164-10.3629-1.68473.3283-2.910.5778QC'd by ChembridgeInactive0
Inhibitor26.603248.396120Partial curve; partial efficacy-4.57514.95490.9177-49.2222-0.826-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-46.4351-2.3640.3688-9.6388-2.3442-2.041-0.00221.4733.1991-2.8675-0.6678-2.01651.02016.8251-11.741-46.4351QC'd by NCIInhibitor26.603240.019410Single point of activity-4.57514.95490.7816-36.0194
Inhibitor21.131779.094741Partial curve; high efficacy-4.67513.51170.7387-73.1775.9177-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-68.1538-0.9821-2.4893-8.8857-2.70951.21070.3298-0.1518-3.40975.743516.504521.713139.4410.1435-33.7222-68.1538QC'd by NCIInhibitor33.491568.810410Single point of activity-4.47514.95490.782-64.8654
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: TRV455
Protocol: Tox21 Assay Protocol Summary:

GH3.TRE-Luc cells were dispensed at 1500 cells/4 uL/well into 1536-well white solid bottom plates using a Multidrop Combi dispenser (Thermo Fisher Scientific Inc., Waltham, MA). After the assay plates were incubated at 37 C for 4 hours, 23 nL of library compound or DMSO controls was transferred to the assay plates by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 ul of T3 (1 nM, final concentration in the wells) to stimulate TR transactivation. The assay plates were incubated at 37 C for 23.5 h, and then 1 uL of CellTiter-Fluor reagent (Promega, Madision, WI) of measuring cytotoxicity was added to each well using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA). The plates were incubated at 37C and 5% CO2 for additional 30 min, and fluorescence intensity was measured by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001392246 uM-Replicate_1Activity at 0.0002720894 uM-Replicate_1Activity at 0.0005955118 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.762 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.793 uM-Replicate_1Activity at 8.439 uM-Replicate_1Activity at 18.15 uM-Replicate_1Activity at 32.49 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04.95490.51575.6094-10.526140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-27.8709-9.58131.553-23.1602-8.9484-8.346419.02864.562714.53951.15650.42210.27193.49757.10181.1664-27.8709QC'd by NCIInactive0
Cytotoxic11.8832114.332782Complete curve; high efficacy-4.92513.92950.9541-100.920113.4126-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-95.18524.113126.147419.56668.33238.270922.114823.359311.62112.5923-0.271521.57888.2783-15.4501-95.7853-95.1852QC'd by NCICytotoxic13.3332101.165782Complete curve; high efficacy-4.87513.51170.924-104.4065
Cytotoxic33.491569.601420Single point of activity-4.47514.50450.5249-51.740917.8605-30 1 0 0 0 0 0 0 0 0 0 0 0 0 0-39.633934.934439.865511.20360.12813.12894.307410.103240.163543.97149.337135.80113.21470.805410.5036-39.6339QC'd by NCIInconclusive10.590945.114210Single point of activity-4.97510.80.518447.3375
Cytotoxic8.412795.006983Complete curve; high efficacy-5.07511.96730.9579-102.9662-7.9593-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-94.1612-1.6767-10.7501-18.3328-8.44320.3012-1.3116-10.0891-5.1512-10.2638-22.1904-3.3436-24.9807-62.5458-94.2914-94.1612QC'd by SigmaAldrichCytotoxic11.883290.158242Partial curve; high efficacy-4.92511.59360.9327-91.6733
Cytotoxic7.497881.846383Complete curve; high efficacy-5.12512.33320.9281-89.6388-7.7925-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-91.0963-18.97671.8287-17.872-12.3952-7.6161-16.3335-2.8335-2.6272-3.7796-9.8936-2.6598-12.2011-70.0356-74.6023-91.0963QC'd by NCICytotoxic7.497889.379383Complete curve; high efficacy-5.12512.40640.958-91.4223
Inactive049.32249.077510.90740.011913.6377.6888-14.85723.0077-6.11470.1121-5.92519.31916.946521.403721.67069.3224QC'd by NCIInactive0
Inactive048.728114.5817-0.06687.0683-0.16080.00131.578912.1056-2.13575.0113.2012-0.24876.3162-7.20095.40878.7281QC'd by NCIInactive04.95490.3678-32.6446
Inactive01.96730.466926.51032.587640 0 0 0 0 0 0 0 0 0 0 0 0 0 026.33589.20266.9567-7.84944.72089.308420.04687.737-11.6312.3017-13.68133.162210.305816.449622.830726.3358QC'd by NCIInactive03.06540.3751-0.4202
Cytotoxic26.603233.620Partial curve; partial efficacy; poor fit-4.57513.990.6032-35.6-2-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-32.1667-19.4025-0.1543-0.2262-0.0757-11.09324.6638-6.5718-3.54455.09010.036-2.1840.10135.1383-12.1502-32.1667QC'd by NCIInactive0
Cytotoxic29.849380.614440Partial curve; high efficacy-4.52513.24750.7249-82.8026-2.1882-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-67.04879.32489.4674-17.343-9.0088-18.8502-4.8122-4.1352-5.0412-6.7317-5.864410.034619.8329-8.8964-20.6155-67.0487QC'd by LabotestCytotoxic29.849363.527240Partial curve; partial efficacy-4.52512.72020.9071-66.8238
Cytotoxic13.3332104.692182Complete curve; high efficacy-4.87513.51170.9601-100.33534.3568-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-99.17277.15452.81146.9308-0.1572-4.105825.3068-0.15731.08666.05980.85484.7774-0.6992-14.6485-90.6892-99.1727QC'd by NCICytotoxic16.7855114.729642Partial curve; high efficacy-4.77512.25260.9303-115.7849
Cytotoxic26.603293.069640Partial curve; high efficacy-4.57512.58840.7505-86.42426.6454-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-68.9291-25.457521.195211.0147-3.417213.682328.16354.114810.73649.90963.39471.32276.46260.2705-23.9356-68.9291QC'd by NCICytotoxic26.603283.904440Partial curve; high efficacy-4.57513.62720.9084-83.7035
Inactive0418.582530.92839.765411.01316.57590.04867.97495.3184.25971.95691.324516.866511.719816.94696.665118.5825QC'd by NCIInactive0
Cytotoxic10.590994.271582Complete curve; high efficacy-4.97512.72020.9664-98.4917-4.2203-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-93.2687-12.6266-9.71552.76191.16913.9341-2.1458-8.3456-7.78480.2987-4.4158-14.4266-11.7198-37.3785-91.2452-93.2687QC'd by NCICytotoxic10.590995.537682Complete curve; high efficacy-4.97512.40640.9837-98.3736
Inactive0421.512319.121525.006-1.94118.35391.0147-1.112212.94014.543614.711516.23313.403818.402626.76119.601221.5123QC'd by NCIInactive0
Inactive02.53340.618314.3567-5.901840 0 0 0 0 0 0 0 0 0 0 0 0 0 1-7.9449-6.97990.27957.2032-12.5846-2.9847-20.5724-7.1225-1.8195.056311.806413.728118.906723.71122.022-7.9449QC'd by NCICytotoxic33.491533.929720Single point of activity-4.47514.95490.5032-33.6955
Inactive0422.09676.01187.77648.964524.48872.336215.856811.60168.99512.18910.87535.056316.9556-9.06529.599522.0967QC'd by NCIInactive02.24810.359418.3831
Inactive04.95490.412622-0.482840 0 0 0 0 0 0 0 0 0 0 0 0 0 016.1783-1.3463-1.5399-1.530212.584-0.6727.8822-4.87790.9615-0.7224-1.1373-9.9856-1.498-1.70110.588816.1783QC'd by ChembridgeInactive0
Cytotoxic29.849359.759320Single point of activity-4.52514.95490.7823-51.55738.202-30 0 0 0 0 1 0 0 0 0 0 0 0 0 0-45.047813.2325.4558-6.067513.70124.8368-25.68159.851213.6578.28768.3941-6.470517.960418.9919-1.1526-45.0478QC'd by NCICytotoxic33.491560.182320Single point of activity-4.47514.95490.9381-56.7139
Cytotoxic33.491577.960640Partial curve; high efficacy-4.47513.51170.6902-85.5053-7.5447-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-67.8614-23.92-6.4036-24.81696.0929-7.6795-2.09631.7283-20.9170.4558-10.7547-17.85467.586-12.7766-19.5831-67.8614QC'd by NCICytotoxic33.491567.176140Partial curve; high efficacy-4.47514.95490.7237-73.9128
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: CPF001
Protocol: HEK 293, NIH 3T3, CRL-7250, HACAT and KB 3-1 cells were seeded into white 1536-well plates using a Multidrop Combi peristaltic dispenser (ThermoFisher, Waltham, MA) at a density of 250, 400, 500, 500, 500 cells/well in 5 uL of medium respectively. A pintool (Kalypsys) was used to transfer 23 nL of compound solution to the 1536-well assay plates. After 48 or 72 hr incubation at 37 degree celcius, 5% CO and 95% humidity, 2.5 uL of CellTiter-Glo (Promega) was dispensed into each well using a dispenser (Aspect Automation, St. Paul, MN) with solenoid valves (Lee Valves, Westbrook CT). Plates were left at room temperature for 10 min before imaging the ATP-coupled luminescence using a ViewLux microplate imager (PerkinElmer, Waltham, MA).
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. Please refer to ACTIVITY_SCORE for each individual cell line. For all inactive compounds, ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000060205 uMActivity at 0.0000300955 uMActivity at 0.0000624651 uMActivity at 0.0001389779 uMActivity at 0.0003184034 uMActivity at 0.0006683289 uMActivity at 0.00130 uMActivity at 0.00271 uMActivity at 0.00492 uMActivity at 0.00762 uMActivity at 0.016 uMActivity at 0.038 uMActivity at 0.071 uMActivity at 0.176 uMActivity at 0.355 uMActivity at 0.588 uMActivity at 1.372 uMActivity at 1.908 uMActivity at 4.964 uMActivity at 9.273 uMActivity at 17.43 uMActivity at 44.77 uMActivity at 91.96 uMActivity at 155.1 uMActivity at 231.0 uMActivity at 0.0000073700 uMActivity at 0.0000316373 uMActivity at 0.0000755538 uMActivity at 0.0001736587 uMActivity at 0.0003606937 uMActivity at 0.0007618542 uMActivity at 0.00133 uMActivity at 0.00262 uMActivity at 0.00635 uMActivity at 0.00856 uMActivity at 0.017 uM
Inactive0-6.08624.95490.8467-19.0684-1.540 0 0 0 0 0 12.118100-8.34361.8417-20.8904-17.20922.1181
Inactive00043.093704.02863.4263-3.42834.65930.95863.0937
Inactive0-8.43624.95490.60020-10.442940 0 0 0 0 0 1-5.6741-7.8694.8276000-3.665-5.6741
Inactive0004-1.22691.59440.8268-6.8139003.009-1.2269
Inactive00040000.646
Inactive00042.016104.739100.507404.00372.0161
Inactive00040-58.9387-0.658900.7761-3.050100
Inactive0-5.38623.57220.9641-17.9156140 0 0 0 0 0 10001.05953.84450-17.0130
Inactive0004-1.61750000-31.91564.5285-1.6175
Inactive000403.5826.95880
Inactive00044.1629-0.06810-0.13403.503204.1629
Inactive00040.0775-4.4477004.2892-3.083200.0775
Inactive0004-4.2864-6.2990000-3.464-4.2864
Inhibitor20.230130.466710Partial curve; partial efficacy; poor fit-4.6944.95490.9513-30.9667-0.5-2.40 0 0 0 0 0 0-27.47223.59671.00910-2.7438-3.3305-0.4297-27.4722
Inactive000406.34610
Inactive0004-5.47750-1.336404.40630-3.1548-5.4775
Inactive00042.2138-0.3090-3.3277-5.07761.864902.2138
Inactive0004-6.8569-2.008600000-6.8569
Inhibitor20.2301111.05610Single point of activity-4.6944.95490.9964-109.52221.5338-30 0 0 0 0 0 0-97.61333.530.1744-1.61494.641802.914-97.6133
Inactive0-4.6944.95490.8369-20.4658340 0 0 0 0 0 0-17.88822.63860
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.10310.1406-0.03150.12620.060.1031QC'd by "NCI"0
Inactive040.02-0.0462-0.0096-0.0036-0.06880.02QC'd by "NCI"0
Inactive040.0352-0.02430.01330.08820.02270.0352QC'd by "NCI"0
Inactive04-0.0032-0.14120.03560.0067-0.0827-0.0032QC'd by "SigmaAldrich"0
Inactive04-0.0421-6.0E-4-0.01160.00418.0E-4-0.0421QC'd by "NCI"0
Inactive04-0.08870.05490.011900.0103-0.0887QC'd by "NCI"0
Inactive040.05490.14040.09660.0264-0.00150.0549QC'd by "NCI"0
Inactive04-0.0674-0.0024-0.1251-0.0771-0.0044-0.0674QC'd by "NCI"0
Inactive040.07660.11210.11820.1033-0.02320.0766QC'd by "NCI"0
Inactive040.02350.0289-0.01920.0237-0.01010.0235QC'd by "Labotest"0
Inactive04-1.0E-40.04880.0010.01740.0628-1.0E-4QC'd by "NCI"0
Inactive04-0.00820.10220.09650.07640.0317-0.0082QC'd by "NCI"0
Inactive040.04070.1229-0.00830.10480.07010.0407QC'd by "NCI"0
Inactive04-0.0682-0.10260.0427-0.0797-0.01-0.0682QC'd by "NCI"0
Inactive04-0.01790.0067-0.06430.0889-0.0161-0.0179QC'd by "NCI"0
Inactive04-0.0027-0.0933-0.0538-0.0212-0.0192-0.0027QC'd by "NCI"0
Inactive04-0.0156-0.0199-0.013-0.0358-0.0233-0.0156QC'd by "NCI"0
Inactive040.03220.01980.0576-0.00580.03020.0322QC'd by "Chembridge"0
Inactive040.10750.08580.07490.0633-0.01660.1075QC'd by "NCI"0
Inactive04-0.186-0.0569-0.018-0.0052-0.0633-0.186QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a [Homo sapiens]
External ID: AROA258
Protocol: Tox21 Assay Protocol Summary:

MCF-7 aro ERE cells were cultured in assay medium (Phenol red-free MEM containing 10% charcoal stripped FBS) two days prior to the assay. The cells were dispensed at 1,500 cells/4 uL/well into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of Testosterone (0.5 nM, final concentration in the wells) using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN). The plates were incubated at 37C and 5% CO2 for 24 h. After the plates were incubated at 37C and 5% CO2 for 23.5 h, 1 uL of CellTiter-Fluor reagent (Promega, Madison, WI) of measuring cytotoxicity was added using a Bioraptr FRD workstation. The assay plates were incubated at 37C and 5% CO2 for additional 30 min and the fluorescence intensity was quantified by a ViewLux plate reader (PerkinElmer, Shelton, CT). For measuring luciferase reporter gene activity, 4 uL of ONE-Glo reagent (Promega) was added to each plate using a Bioraptr FRD and luminescence was quantified on a ViewLux (PerkinElmer) plate reader after 30 min incubation at room temperature.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002720541 uM-Replicate_1Activity at 0.0005955401 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00614 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.341 uM-Replicate_1Activity at 0.763 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 32.48 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04-2.2066-1.1536-4.2174-8.711-6.6426-5.9488-2.0391-15.718-3.7027-4.5545-2.2801-3.7857-12.9599-13.1214-9.6886-2.2066QC'd by SigmaAldrichInactive00.60.524216
Inhibitor4.8311106.123784Complete curve; high efficacy-5.3163.92950.9965-109.1556-3.0318-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-111.611-2.2326-0.9982-2.1761-2.6217-1.2536-0.6776-10.6612-7.1504-2.5933-3.3688-27.6728-95.4648-108.5642-108.8003-111.611QC'd by SigmaAldrichInhibitor9.6393108.044283Complete curve; high efficacy-5.0162.33320.9737-111.3141
Inactive040.5035-0.5614-0.60061.8325-12.3047-7.0616-6.7801-7.5450.0745-7.0388-14.6296-17.129-10.3065-10.04952.84210.5035QC'd by SigmaAldrichInactive00.40.712212
Activator4.786735.1920Complete curve; partial efficacy-5.321.96730.788739.93654.74451.20 0 0 0 0 0 0 0 0 0 0 0 0 0 029.03948.85029.48829.65431.80068.671-15.61197.826913.14394.80715.616715.517731.452742.742446.782229.0394QC'd by SIGMAActivator6.026139.15410Partial curve; partial efficacy-5.220.90.716642.3193
Inactive0413.107-3.69333.8384-3.8759-2.794915.10135.67543.9491-0.481-0.0087-1.35722.7430.4844-0.2286-0.506613.107QC'd by SigmaAldrichInactive0
Inactive00.30.591126140 0 0 0 0 0 0 0 0 0 0 0 0 0 016.5070.22480.16584.54288.20863.07311.62359.30792.96323.47696.953417.436117.45098.245520.704216.507QC'd by SIGMAInactive0
Inactive00.50.6093342.518640 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0871-0.04994.374311.83183.87946.24796.7535-0.81793.25538.241615.0466.393516.677312.040126.46280.0871QC'd by SIGMAInactive0
Inactive049.877725.13764.246517.21280.730714.42964.63272.88386.0378.01461.82367.76-0.9897-0.539911.31369.8777QC'd by SIGMAInactive0
Inactive03.1320.3295-2.85236.540 0 0 0 0 0 0 0 0 0 0 0 0 0 114.23829.08182.781819.61592.0565.20476.73762.60575.76535.52163.30952.0753-14.0436-1.25855.163414.2382QC'd by SIGMAInactive00.90.596219
Inactive04-8.817950.49373.29484.0553-0.6701-0.6623-1.2923-7.08623.7302-10.61697.0748-9.6132-5.8222-0.2724-6.1574-8.8179QC'd by SIGMAInactive02.40640.4689-16.5545
Inactive048.37919.77034.99511.86981.2146-1.77476.29237.9265.26814.22540.00622.72662.48328.463714.10848.3791QC'd by SIGMAInactive00.60.514216
Inactive04-8.27240.0281-1.4766-2.28621.25773.831-0.44142.53031.7269-0.7283-1.5332-1.491-14.22041.08090.4188-8.2724QC'd by SigmaAldrichInactive0
Inactive04.95490.3969-6.05574.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.12147.3682.91070.72930.8159.56672.9381-11.3075-8.80042.3752.7959-1.0346-18.7964-0.6442-13.2151-0.1214QC'd by SigmaAldrichInactive0
Inactive041.44823.58520.4997-0.7201-9.4521-0.6989-1.3229-8.92980.74661.0939-11.5869-1.93430.8104-13.6039-1.16031.4482QC'd by SIGMAInactive02.33320.623112.5
Inhibitor60.261387.346841Partial curve; high efficacy-4.223.19250.9468-91.7081-4.3613-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-73.2637-0.7151-1.4324-8.64940.3488-1.0106-0.8286-10.6048-2.9472-0.5851-2.1641-10.2189-13.2296-5.2897-23.1809-73.2637QC'd by SigmaAldrichInhibitor53.707981.468141Partial curve; high efficacy-4.273.92950.9434-84.2519
Inactive04.95490.5801-7.1836-0.829740 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.1223-1.2322-1.1081-1.7584-8.8414-5.325-10.4209-6.1753-4.2522-4.2314-10.9863-7.5165-5.1054-7.8585-8.4654-9.1223QC'd by ChemServiceInactive04.95490.35784.5
Inhibitor24.3613103.983841Partial curve; high efficacy-4.61332.35310.9238-97.82326.1605-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.92071.595-3.3685-2.9295-0.3657-0.674810.0521.01462.20929.916924.275426.29-4.4212-30.9132-70.0689-96.9207QC'd by SIGMAInhibitor27.3338108.053740Partial curve; high efficacy-4.56331.98870.9107-103.8107
Inactive04-1.8107-0.19851.1239-2.7571-9.5761-2.0759-8.4016-9.53090.2125-1.6114-8.3569-1.504-7.968-1.193-6.8529-1.8107QC'd by SigmaAldrichActivator42.969237.94450Partial curve; partial efficacy-4.36682.72020.911335.5
Inactive04-0.8051-6.3306-0.3852-7.0596-0.1656-3.4084-6.7899-11.8797-7.7193-10.2069-7.5291-14.8365-8.1408-1.5169-2.1071-0.8051QC'd by SigmaAldrichActivator0.436315.75320Complete curve; partial efficacy; poor fit-6.36024.95490.518712.5053
Inactive04-0.53480.5678-2.8997-2.84370.38943.491-6.100814.436-0.80381.870613.74841.2268-0.08231.5329-0.0037-0.5348QC'd by SigmaAldrichInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.06820.17150.15520.2805-0.08310.0682QC'd by "APAC"0
Inactive040.0073-0.03930.005-0.09740.03070.0073QC'd by "APAC"0
Inactive04-0.4123-0.248-0.1541-0.1037-0.0973-0.4123QC'd by "APAC"0
Inactive040.19330.41050.28830.44640.38910.1933QC'd by "APAC"0
Inactive040.44160.65360.7260.63220.73960.4416QC'd by "APAC"0
Inactive040.2127-0.00470.08240.2587-0.01090.2127QC'd by "APAC"0
Inactive040.13480.40170.15030.02750.21030.1348QC'd by "APAC"0
Inactive040.16380.07840.19640.35280.10370.1638QC'd by "APAC"0
Inactive04-0.0775-0.1328-0.144-0.2205-0.105-0.0775QC'd by "APAC"0
Inactive040.12810.06390.0321-0.01010.04060.1281QC'd by "APAC"0
Inactive04-0.4235-0.3306-0.3534-0.2876-0.4525-0.4235QC'd by "APAC"0
Inactive040.1880.24950.21320.11330.30530.188QC'd by "APAC"0
Inactive040.26490.13370.33710.1823-0.01240.2649QC'd by "APAC"0
Inactive040.14720.44310.35470.41120.45620.1472QC'd by "APAC"0
Inactive040.18370.1140.0230.16450.38450.1837QC'd by "APAC"0
Inactive04-0.5082-0.4883-0.5711-0.5038-0.4992-0.5082QC'd by "APAC"0
Inactive04-0.2494-0.1585-0.0187-0.265-0.2494-0.2494QC'd by "APAC"0
Inactive04-0.489-0.6545-0.2063-0.2875-0.5573-0.489QC'd by "APAC"0
Inactive04-0.1512-0.1725-0.2697-0.1595-0.2932-0.1512QC'd by "APAC"0
Inactive040.1730.29550.30070.26150.34070.173QC'd by "APAC"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-activator-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Activator112.20182659.1944100Partial curve; high efficacy-3.954.50450.99882689.2430.04562.10 0 0 0 0 02175.7605-2.186418.44120.797383.3849426.79582175.7605QC'd by Microsource
Activator0.1778128.312895Complete curve; high efficacy-6.754.95490.9927134.48516.17231.10 0 0 0 0 114.5095.603324.7938142.7655131.831127.775314.509QC'd by SigmaAldrich
Activator0.4467126.107791Complete curve; high efficacy-6.351.86170.9998123.6363-2.47141.10 0 0 0 0 10.2688-2.58447.816180.257120.2764123.38950.2688QC'd by SigmaAldrich
Activator1.122117.125490Complete curve; high efficacy-5.952.24810.9788132.426515.30111.10 0 0 0 0143.318715.809439.5652122.9227119.7824143.3187QC'd by Tocris
Activator112.20181122.177671Partial curve; high efficacy-3.954.50450.99831140.568818.39122.10 0 0 0 0922.79033.23057.588941.6506204.8302922.7903QC'd by Timtec
Activator100709.567358Partial curve; high efficacy-43.990.9988700.7079-8.85942.10 0 0 0 0 0592.8155-15.9019-8.65324.5286-20.153176.4838592.8155QC'd by CarsonNewman-SPECS
Activator79.4328826.407657Partial curve; high efficacy-4.14.0950.9972826.76670.35912.10 0 0 0 0 0665.6736-2.5729-3.4508-16.761725.5851154.5978665.6736QC'd by Prestwick Chemical; Inc.
Activator100589.932555Partial curve; high efficacy-43.24750.984613.297923.36542.10 0 0 0 0 0498.6162-5.7471.05937.654362.5313194.9599498.6162QC'd by CarsonNewman-SPECS
Activator112.2018558.656655Partial curve; high efficacy-3.954.50450.9992557.2619-1.39472.10 0 0 0 0448.681-6.8565-3.87677.063281.1858448.681QC'd by Vitas
Activator100612.475355Partial curve; high efficacy-44.50450.9972611.2868-1.18852.10 0 0 0 0 0533.4091-10.048-5.6002-8.206821.4265142.7223533.4091QC'd by Pharmacopeia
Activator100511.551853Partial curve; high efficacy-44.44950.9965517.54675.9952.10 0 0 0 0 0453.9884-10.486710.44483.974421.1983121.4017453.9884QC'd by CarsonNewman-SPECS
Activator112.2018440.198152Partial curve; high efficacy-3.954.0950.9989439.2753-0.92282.10 0 0 0 0348.6312-5.1918-3.30186.970574.6909348.6312QC'd by Sequoia
Activator100497.63552Partial curve; high efficacy-43.67720.9977486.8252-10.80982.10 0 0 0 0 0401.671-14.9427-21.3461-13.18642.6858130.5049401.671QC'd by Pharmacopeia
Activator100438.508551Partial curve; high efficacy-44.95490.9987437.7956-0.71282.10 0 0 0 0 0392.29-7.25310.2913-4.1769.366693.145392.29QC'd by Pharmacopeia
Activator56.2341819.971850Partial curve; high efficacy-4.253.24750.9993802.9227-17.0492.10 0 0 0 0787.1792-7.4836-10.9833-14.2075580.1833787.1792QC'd by NCI
Activator112.2018363.64150Partial curve; high efficacy-3.954.95490.9972355.9752-7.66582.10 0 0 0 0 0293.7089-16.73630.4741-6.1211-4.368934.2599293.7089QC'd by Pharmacopeia
Activator112.2018363.029750Partial curve; high efficacy-3.954.50450.9992370.42997.40022.10 0 0 0 0 0299.70063.69434.700413.02825.857563.7543299.7006QC'd by Pharmacopeia
Activator100295.813448Partial curve; high efficacy-43.62720.9992302.03896.22552.10 0 0 0 0 0251.69912.67988.48118.67789.650486.3825251.6991QC'd by CarsonNewman-SPECS
Activator100233.346946Partial curve; high efficacy-44.50450.9961221.7227-11.62422.10 0 0 0 0 0192.4676-6.6471-16.5394-18.4762-5.603142.3638192.4676QC'd by CarsonNewman-SPECS
Activator112.2018234.606146Partial curve; high efficacy-3.954.95490.984235.23560.62952.10 0 0 0 0 0197.01480.9163-4.51361.948217.44218.7867197.0148QC'd by Pharmacopeia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:RecName: Full=Cellular tumor antigen p53; AltName: Full=Antigen NY-CO-13; AltName: Full=Phosphoprotein p53; AltName: Full=Tumor suppressor p53
External ID: P53823
Protocol: Please refer to other AIDs, 651631 and 651633, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the P53 assay (AID 651631) and cell viability counter screen (AID 651633). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Viability ActivityViability Potency (uM)Viability Efficacy (%)Sample Source
inactiveinactive0inactive0inconclusive agonist15.55089081inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusive agonistinconclusive agonist18.58791134inactive0active agonist29.8492948138.73741641inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusiveactive agonist28.7254875625.5057883active antagonist29.84929481-51.18360188inactive0active antagonist29.84929481-98.84256078SigmaAldrich
inconclusiveinconclusive agonist14.35525499inconclusive antagonist31.61797672-26.09239449inactive0active antagonist26.603212-72.63099375NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inconclusive antagonistLabotest
inconclusiveactive agonist33.4914596364.83524463active antagonist33.49145963-59.84708639inactive0inconclusive antagonist28.17955142-95.15844265NCI
inconclusive agonistinconclusive agonist10.75907896inactive0active agonist19.07705083inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inconclusiveinconclusive agonist33.4914596379.63843875inconclusive antagonist31.61797672-53.76954664inactive0active antagonist29.84929481-106.2599059NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0NCI
inactiveinactive0inactive0inactive0inactive0Chembridge
inactiveinactive0inactive0inactive0inactive0NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0303-0.04260.0285-0.09190.0085-0.0303QC'd by "NCI"0
Inactive040.0853-0.06580.02019.0E-40.06280.0853QC'd by "NCI"0
Inactive040.16730.04180.01560.0204-0.00980.1673QC'd by "NCI"0
Inactive04-0.1980.02190.0160.02350.0689-0.198QC'd by "SigmaAldrich"0
Inactive040.0038-0.0014-0.00825.0E-4-0.1170.0038QC'd by "NCI"0
Inactive040.0026-0.0041-0.01760.0697-0.01480.0026QC'd by "NCI"0
Inactive040.1333-0.0845-0.0206-0.01310.12030.1333QC'd by "NCI"0
Inactive040.03690.00440.0618-0.01070.01570.0369QC'd by "NCI"0
Inactive04-0.02150.02550.01530.1030.0492-0.0215QC'd by "NCI"0
Inactive04-0.00280.08780.0034-0.01623.0E-4-0.0028QC'd by "Labotest"0
Inactive040.02210.0083-0.0285-0.04060.10790.0221QC'd by "NCI"0
Inactive040.02430.10020.08470.0514-0.00220.0243QC'd by "NCI"0
Inactive040.00680.024-0.00130.0328-0.11050.0068QC'd by "NCI"0
Inactive040.03090.0251-0.2255-0.1044-0.07930.0309QC'd by "NCI"0
Inactive04-0.0428-0.0779-0.07410.0110.0229-0.0428QC'd by "NCI"0
Inactive040.07660.0357-0.02130.0861-0.01260.0766QC'd by "NCI"0
Inactive04-0.0349-0.0548-0.0746-0.0452-0.1742-0.0349QC'd by "NCI"0
Inactive040.15650.01040.0178-0.0320.02410.1565QC'd by "Chembridge"0
Inactive04-0.05070.0691-0.01840.01950.0897-0.0507QC'd by "NCI"0
Inactive04-0.0232-0.1816-0.1161-0.2126-0.2187-0.0232QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-inhibitor-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.78241.505912.540 0 0 0 0 02.50148.657916.73337.679-0.41183.23982.5014QC'd by Pharmacopeia
Inactive04.95490.5059222.540 0 0 0 0 06.253623.167131.574120.397112.323123.69316.2536QC'd by Pharmacopeia
Inactive03.06540.487561440 0 0 0 0 07.117813.853713.063510.239619.91049.84967.1178QC'd by Pharmacopeia
Inactive04.95490.8513-6.122214.540 0 0 0 0 0-2.601918.618115.697111.958910.649712.3116-2.6019QC'd by Pharmacopeia
Inactive04.95490.4441-8.935340 0 0 0 0 04.128-6.61282.85915.135-4.2457-1.68664.128QC'd by Pharmacopeia
Inactive00.90.60781.5740 0 0 0 0 03.28024.93557.52122.24671.45360.76263.2802QC'd by Pharmacopeia
Inactive0415.807823.846715.21025.400717.117711.703815.8078QC'd by Pharmacopeia
Inactive04-4.32494.35640.9262-8.26096.61363.2318-4.3249QC'd by Pharmacopeia
Inactive04.95490.3866.51640 0 0 0 0 118.561314.469622.616710.242516.25858.074118.5613QC'd by Pharmacopeia
Inactive04.95490.793515-5.385140 0 0 0 0 016.1015-1.154320.964112.456114.239511.422716.1015QC'd by Pharmacopeia
Inactive04.50450.947310.52240 0 0 0 0 08.684621.396522.306312.781710.406512.7248.6846QC'd by Pharmacopeia
Inactive00.90.72282.68042640 0 0 0 0 0-2.766319.58196.42455.7298.03594.8741-2.7663QC'd by Pharmacopeia
Inactive04.44950.86116.58.540 0 0 0 0 19.3158.510610.85386.227115.368416.53989.315QC'd by Pharmacopeia
Inactive04.95490.574110.50.708340 0 0 0 0 012.21914.1249-2.326514.46343.839910.786612.2191QC'd by Pharmacopeia
Inactive049.708413.42218.37480.333810.101818.04579.7084QC'd by Pharmacopeia
Inactive04.95490.4502-7.41418.540 0 0 0 0 0-4.51189.055914.9898-2.014610.28748.4395-4.5118QC'd by Pharmacopeia
Inactive04.95490.6758280.244340 0 0 0 0 023.04957.0826-6.46314.13492.386-6.030223.0495QC'd by Pharmacopeia
Inactive04.44950.7608-2.59256.540 0 0 0 0 18.96953.44595.67689.8855-0.0456-2.16048.9695QC'd by Pharmacopeia
Inactive02.63840.66513.52040 0 0 0 0 013.574216.035922.509821.272319.386214.340813.5742QC'd by Pharmacopeia
Inactive04-3.2632-16.2622-13.7616-11.6684-9.5243-17.6211-3.2632QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (DMEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.060.0769-0.0561-0.05340.0765-0.06QC'd by "NCI"0
Inactive04-0.02860.01850.15430.03970.0134-0.0286QC'd by "NCI"0
Inactive041.25510.11730.01450.07070.51551.2551QC'd by "NCI"0
Inactive040.0380.0229-0.1395-0.01880.42040.038QC'd by "SigmaAldrich"0
Inactive041.3250.07660.1836-0.10240.07711.325QC'd by "NCI"0
Inactive040.1088-0.12430.0941-0.0246-0.04550.1088QC'd by "NCI"0
Inactive040.00260.0529-0.1116-0.1678-0.11720.0026QC'd by "NCI"0
Inactive040.17340.0511-0.06420.11-0.13760.1734QC'd by "NCI"0
Inactive040.0031-0.0257-0.0731-0.021-0.01490.0031QC'd by "NCI"0
Inactive04.0950.98722.5040 0 0 0 02.51080.00570.26280.01340.77542.5108QC'd by "Labotest"0
Inactive04-0.05950.0115-0.03130.04540.0652-0.0595QC'd by "NCI"0
Inactive040.7551-0.0030.0690.14220.06940.7551QC'd by "NCI"0
Inactive04-0.0762-0.099-0.14750.0756-0.1338-0.0762QC'd by "NCI"0
Inactive040.0533-0.1182-0.00850.0808-0.08810.0533QC'd by "NCI"0
Inactive041.4117-0.0519-0.0295-0.05670.23241.4117QC'd by "NCI"0
Inactive040.15250.02280.10290.03280.11910.1525QC'd by "NCI"0
Inactive040.97520.1286-0.0289-0.0041-0.01590.9752QC'd by "NCI"0
Inactive040.090.11160.0522-0.0224-0.17680.09QC'd by "Chembridge"0
Inactive040.12760.09120.04220.0790.08710.1276QC'd by "NCI"0
Inactive04-0.05040.00170.0374-0.2014-0.0226-0.0504QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MG
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0468-1.0E-4-0.0634-0.0128-0.1309-0.0468QC'd by "NCI"0
Inactive04-0.02170.0466-0.04120.00330.0551-0.0217QC'd by "NCI"0
Inactive04-0.0248-0.00450.0622-0.03730.0284-0.0248QC'd by "NCI"0
Inactive040.01860.0540.055-7.0E-40.08120.0186QC'd by "SigmaAldrich"0
Inactive040.02420.07270.1578-0.01480.02860.0242QC'd by "NCI"0
Inactive040.08870.03620.13790.04160.03120.0887QC'd by "NCI"0
Inactive040.10310.0424-0.0028-0.06470.0120.1031QC'd by "NCI"0
Inactive040.022-0.01990.0104-0.01420.03070.022QC'd by "NCI"0
Inactive040.58190.1190.05910.03290.05860.5819QC'd by "NCI"0
Inactive04-0.01230.04580.0457-0.03880.0399-0.0123QC'd by "Labotest"0
Inactive04-0.0094-0.02560.0289-0.00760-0.0094QC'd by "NCI"0
Inactive040.11950.07450.00670.004-0.05970.1195QC'd by "NCI"0
Inactive04-0.0059-0.05640.01470.0049-0.0156-0.0059QC'd by "NCI"0
Inactive04-0.05470.0295-0.0247-0.0665-0.0356-0.0547QC'd by "NCI"0
Inactive04-0.0413-0.0059-0.1195-0.0027-0.0175-0.0413QC'd by "NCI"0
Inactive040.175-0.00450.11290.06590.06270.175QC'd by "NCI"0
Inactive04-0.0317-0.0316-0.01050.0141-0.0074-0.0317QC'd by "NCI"0
Inactive040.06210.0243-0.0520.16910.01120.0621QC'd by "Chembridge"0
Inactive040.0158-0.02480.0493-0.0242-0.02880.0158QC'd by "NCI"0
Inactive04-0.0654-0.1331-0.0734-0.03930.0109-0.0654QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive040.2003-0.01150.00710.23730.09540.2003QC'd by "NCI"0
Inactive040.1113-0.03910.08984.0E-4-0.03890.1113QC'd by "NCI"0
Inactive04-0.09730.0277-0.0084-0.00980.0055-0.0973QC'd by "NCI"0
Inactive04-0.1827-0.0289-0.0224-0.1537-0.0181-0.1827QC'd by "SigmaAldrich"0
Inactive040.5452-0.03350.0032-0.01370.01630.5452QC'd by "NCI"0
Inactive04-0.05130.011-0.0106-0.0503-0.0065-0.0513QC'd by "NCI"0
Inactive04-0.0252-0.1196-0.0502-0.05650.0376-0.0252QC'd by "NCI"0
Inactive040.10450.0373-0.01590.03940.00210.1045QC'd by "NCI"0
Inactive04-0.24220.0063-0.0071-0.0119-0.0133-0.2422QC'd by "NCI"0
Inactive04.50450.98673040 0 0 0 03.1340.15520.13580.19860.6053.134QC'd by "Labotest"0
Inactive04-0.0090.01850.03930.2310.0436-0.009QC'd by "NCI"0
Inactive040.07510.02710.22620.17550.01740.0751QC'd by "NCI"0
Inactive040.0132-0.0598-0.0350.09430.07230.0132QC'd by "NCI"0
Inactive049.0E-4-0.0911-0.05740.15930.17099.0E-4QC'd by "NCI"0
Inactive040.6834-0.1194-0.00280.3720.19860.6834QC'd by "NCI"0
Inactive040.1104-0.08290.06180.16230.0230.1104QC'd by "NCI"0
Inactive040.5456-0.0786-0.0186-0.0058-0.00230.5456QC'd by "NCI"0
Inactive04-0.1424-0.0976-0.10020.027-0.1146-0.1424QC'd by "Chembridge"0
Inactive040.0252-0.0593-0.08240.12910.04990.0252QC'd by "NCI"0
Inactive040.0384-0.2038-0.1551-0.007-0.01920.0384QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-activator-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00246 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.011 uMActivity at 0.025 uMActivity at 0.045 uMActivity at 0.067 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.8563-9.9979-3.18240 0 0 0 0 0-8.823-2.9167-5.5515-1.8183-11.2482-10.2408-8.823QC'd by Microsource
Inactive01.53860.5644-4.854640 0 0 0 0 1-7.5471-0.6835-9.0455-3.7039-1.19033.153-7.5471QC'd by Microsource
Inactive04.95490.431-21.09492.199340 0 0 0 0 0-29.6624-1.0839-27.7771-29.2982-9.5254-9.846-29.6624QC'd by Microsource
Inactive04.95490.3341-1.3603-6.912440 0 0 0 0 1-15.5699-9.927-2.5767-5.8552-8.5221-2.3836-15.5699QC'd by Microsource
Inhibitor0.891314.13510Complete curve; partial efficacy; poor fit-6.052.12110.6534-22.6728-8.5377-1.40 0 0 0 0 0-21.1521-8.7814-12.9514-21.2535-30.9774-17.0722-21.1521QC'd by Microsource
Inactive03.1320.47250.5-4.228440 0 0 0 0 0-0.2612-1.9763-2.0592-8.107-2.12880.8201-0.2612QC'd by Microsource
Inactive04.95490.4917-10.967-2.314940 0 0 0 0 0-10.1405-1.5124-2.5506-5.4129-17.8892-4.0897-10.1405QC'd by Microsource
Inactive03.990.5924-19.9348040 0 0 0 0 0-28.6957-6.23025.7918-15.0449-23.6413-7.309-28.6957QC'd by Microsource
Inactive04.95490.4102-6.1308540 0 0 0 0 0-4.3550.82898.6021-2.8349-16.3592.161-4.355QC'd by Microsource
Inactive04.95490.369-1.5-14.336940 0 0 0 0 1-9.3021-12.78082.0015-0.2528-12.58754.4401-9.3021QC'd by Microsource
Inhibitor0.707923.62210Complete curve; partial efficacy; poor fit-6.153.06540.6513-24.5288-0.9067-1.40 0 0 0 0 1-13.9864-1.5889-9.6741-27.4469-33.3677-12.1786-13.9864QC'd by Microsource
Inactive04-22.4775-11.6889-11.6628-13.5576-20.9035-8.6191-22.4775QC'd by Microsource
Inactive00.80.7088-25.4933-11.691840 0 0 0 0 0-24.5778-16.5266-8.0765-17.2318-20.0221-22.1348-24.5778QC'd by Microsource
Inhibitor0.177819.99850Complete curve; partial efficacy; poor fit-6.754.95490.6578-21.9347-1.9361-1.40 0 0 0 0 0-23.6561-4.5301-30.7789-20.7284-19.2667-15.4849-23.6561QC'd by Microsource
Inactive010.9184-24.9585-2.733140 0 0 0 0 1-15.8401-9.7776-20.4013-20.4952-26.2154-25.1202-15.8401QC'd by Microsource
Inactive04-16.8662-15.0798-16.9114-17.163-13.1564-16.5558-16.8662QC'd by Microsource
Inactive047.75753.31266.13836.2047-2.02096.22127.7575QC'd by Microsource
Inactive043.75979.79097.02243.0975-6.896512.31463.7597QC'd by Microsource
Inactive04.95490.6335-4.9129640 0 0 0 0 0-8.84676.11915.34965.0731-9.09412.984-8.8467QC'd by Microsource
Inactive04.95490.7097-7.2734040 0 0 0 0 0-5.9151.1538-1.05870.2688-11.4778-4.1213-5.915QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MR
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.12420.2628-0.1782-0.4447-0.2156-0.1242QC'd by "NCI"0
Inactive040.52820.2696-0.353-0.2319-0.17610.5282QC'd by "NCI"0
Inactive040.36990.109-0.00360.2172-0.0050.3699QC'd by "NCI"0
Inactive040.003-0.1398-0.2166-0.05930.03410.003QC'd by "SigmaAldrich"0
Inactive040.0037-0.18840.15210.18170.12320.0037QC'd by "NCI"0
Inactive040.42260.0606-0.0267-0.1598-0.03750.4226QC'd by "NCI"0
Inactive04-0.1083-0.0289-0.054-0.2945-0.072-0.1083QC'd by "NCI"0
Inactive04-0.0618-0.03660.04-0.2576-0.1156-0.0618QC'd by "NCI"0
Inactive040.0450.2884-0.027-0.166-0.30740.045QC'd by "NCI"0
Inactive04-0.2251-0.37-0.4364-0.0983-0.1209-0.2251QC'd by "Labotest"0
Inactive04-0.32420.23140.0134-0.2318-0.0596-0.3242QC'd by "NCI"0
Inactive04-0.01610.01530.03390.01490.0696-0.0161QC'd by "NCI"0
Inactive04-0.00830.0949-0.2516-0.1363-0.3201-0.0083QC'd by "NCI"0
Inactive040.1281-0.3790.11360.0866-0.02890.1281QC'd by "NCI"0
Inactive04-0.0989-0.0902-0.1041-0.2289-0.1987-0.0989QC'd by "NCI"0
Inactive040.0739-0.0110.01860.02430.02880.0739QC'd by "NCI"0
Inactive04-0.20280.08760.015-0.0122-0.012-0.2028QC'd by "NCI"0
Inactive04-0.152-0.0722-0.03940.08260.0334-0.152QC'd by "Chembridge"0
Inactive04-0.0720.1489-0.00810.015-0.0036-0.072QC'd by "NCI"0
Inactive04-0.1159-0.19220.11950.16620.2987-0.1159QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-inhibitor-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009200000 uMActivity at 0.00184 uMActivity at 0.00456 uMActivity at 0.00471 uMActivity at 0.00850 uMActivity at 0.018 uMActivity at 0.034 uMActivity at 0.050 uMActivity at 0.090 uMActivity at 0.151 uMActivity at 0.235 uMActivity at 0.457 uMActivity at 0.814 uMActivity at 1.171 uMActivity at 2.284 uMActivity at 4.113 uMActivity at 5.853 uMActivity at 11.42 uMActivity at 20.49 uMActivity at 29.59 uMActivity at 56.64 uMActivity at 111.7 uMActivity at 150.6 uMActivity at 238.8 uMActivity at 452.6 uMActivity at 611.0 uMCompound QC
Inactive03.62720.8626-16.9749340 0 0 0 0 0-11.35224.4122-0.18693.8551-9.0486-22.4791-11.3522QC'd by SigmaAldrich
Inactive01.210.9115126.540 0 0 0 0 03.087922.522231.966122.849617.27176.55893.0879QC'd by NCI
Inactive00.30.7243-12.89953840 0 0 0 0 0-10.749628.516821.95465.20966.073811.3009-10.7496QC'd by Prestwick Chemical; Inc.
Inactive04.95490.8029-15.6993-1.540 0 0 0 0 0-11.416-1.5504-1.249-4.6581-0.42660.4639-11.416QC'd by BIOMOL
Inactive04.95490.6678-24.46023.435940 0 0 0 0 1-5.46512.8722.434-38.4104-25.2406-9.2436-5.4651QC'd by BIOMOL
Inactive02.40640.421511740 0 0 0 0 05.872919.320214.88288.633224.90711.29795.8729QC'd by BIOMOL
Inactive00.60.7078-8.313814.540 0 0 0 0 0-10.777711.81871.99321.9062-11.5115-0.0866-10.7777QC'd by BIOMOL
Inactive03.990.91612.52940 0 0 0 0 011.321625.351110.278212.692812.042515.059611.3216QC'd by BIOMOL
Inactive04.95490.7598-8.0307240 0 0 0 0 0-6.9632-1.91335.8317-9.609-8.7246-6.018-6.9632QC'd by SigmaAldrich
Inactive00.70.6402-18.8089-2.373540 0 0 0 0 0-14.8407-3.9662-6.7181-0.3112-9.968-9.2615-14.8407QC'd by Microsource
Inactive04.95490.9739-11.7501240 0 0 0 0 0-11.69293.0780.24372.2683-12.7084-10.568-11.6929QC'd by Microsource
Inactive00.50.7605-11.0605640 0 0 0 0 0-14.63373.6876-3.5123-6.8473-7.5675-5.2666-14.6337QC'd by BIOMOL
Inactive04-7.534.7778-6.7829-15.1322-23.6499.0847-7.53QC'd by Prestwick Chemical; Inc.
Inactive04.95490.6409-3.29491440 0 0 0 0 112.981817.6514.10220.62192.497-3.579112.9818QC'd by BIOMOL
Inactive01.82650.7407-32.7287-10.937340 0 0 0 0 0-28.3802-13.7631-19.1044-5.7811-12.8137-32.2739-28.3802QC'd by Tocris
Activator39.810746.5380Single point of activity-4.44.44950.745456.645810.107830 0 0 0 0 117.141513.503225.583214.4646.953849.110217.1415QC'd by SigmaAldrich
Inactive04.95490.5359-17.72063.540 0 0 0 0 0-16.8505-6.86613.1002-5.400912.3928-11.0619-16.8505QC'd by SigmaAldrich
Inactive04.95490.6571.108210.540 0 0 0 0 110.717211.35185.125315.2488-0.32652.247610.7172QC'd by Prestwick Chemical; Inc.
Inactive00.70.842-14.440710.540 0 0 0 0 0-8.700613.02386.27927.28923.56910.9878-8.7006QC'd by BIOMOL
Inactive01.010.87182.4065-26.947540 0 0 0 0 1-20.1909-25.9748-30.373-20.9376-21.2882-7.9946-20.1909QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478MB
Protocol: Tox21 Assay Protocol Summary:

5 uL of culture medium (MEM containing 10% FBS) per well was dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). After 23 nL compound or DMSO vehicle was transferred into assay plate by a pintool work station (Kalypsys, San Diego, CA), fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1115-0.1251-0.0765-0.06640.0949-0.1115QC'd by "SIGMA"0
Inactive04-0.0069-0.10850.02610.0208-0.0462-0.0069QC'd by "SigmaAldrich"0
Inactive04-0.172-0.0309-0.0124-0.0718-0.0262-0.172QC'd by "SIGMA"0
Inactive040.0130.0073-0.01730.01340.00240.013QC'd by "SigmaAldrich"0
Inactive04-0.052-0.0612-0.0736-0.0496-0.0413-0.052QC'd by "SigmaAldrich"0
Inactive04-0.0569-0.01650.10050.1139-0.0959-0.0569QC'd by "SigmaAldrich"0
Inactive04-0.0353-0.0623-0.04670.00960.0134-0.0353QC'd by "SIGMA"0
Inactive040.22820.00980.01520.0163-0.02330.2282QC'd by "Alfa Aesar"0
Inactive04-0.1287-0.0353-0.0866-0.012-0.0014-0.1287QC'd by "SIGMA"0
Inactive04-0.0565-0.1141-0.0255-0.009-0.0415-0.0565QC'd by "SIGMA"Inactive04
Inactive04-0.1244-0.1158-0.0769-0.0272-0.0887-0.1244QC'd by "SIGMA"0
Inactive04-0.1459-0.077-0.0696-0.0992-0.1072-0.1459QC'd by "SIGMA"0
Inactive04-0.0112-0.12120.0729-0.0657-0.1082-0.0112QC'd by "SIGMA"0
Inactive04-0.0758-0.1319-0.0931-0.0564-0.0431-0.0758QC'd by "SIGMA"0
Inactive04-0.0061-0.0301-0.0049-0.0052-0.0205-0.0061QC'd by "SigmaAldrich"0
Inactive040.06630.0020.1992-0.0417-0.05850.0663QC'd by "SigmaAldrich"0
Inactive040.1620.0128-0.0595-0.0493-0.05030.162QC'd by "Interchem"0
Inactive04-0.0217-0.0781-0.08430.00810.004-0.0217QC'd by "SigmaAldrich"0
Inactive040-0.0307-1.0E-4-0.0089-0.03580QC'd by "SigmaAldrich"0
Inactive04-0.02990.0039-0.03650.0192-0.0786-0.0299QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: AROV112
Protocol: Tox21 Assay Protocol Summary:

MCF-7 aro ERE cells were cultured in assay medium (Phenol red-free MEM containing 10% charcoal stripped FBS) two days prior to the assay. The cells were dispensed at 1,500 cells/4 uL/well into white wall/solid-bottom 1536-well plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of Testosterone (0.5 nM, final concentration in the wells) using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN). The plates were incubated at 37C and 5% CO2 for 24 h. After the plates were incubated at 37C and 5% CO2 for 23.5 h, 1 uL of CellTiter-Fluor reagent (Promega, Madison, WI) of measuring cytotoxicity was added using a Bioraptr FRD workstation. The assay plates were incubated at 37C and 5% CO2 for additional 30 min and the fluorescence intensity was quantified by a ViewLux plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000044240 uM-Replicate_1Activity at 0.0000098920 uM-Replicate_1Activity at 0.0000221200 uM-Replicate_1Activity at 0.0000618460 uM-Replicate_1Activity at 0.0001391192 uM-Replicate_1Activity at 0.0002720541 uM-Replicate_1Activity at 0.0005955401 uM-Replicate_1Activity at 0.00123 uM-Replicate_1Activity at 0.00275 uM-Replicate_1Activity at 0.00613 uM-Replicate_1Activity at 0.014 uM-Replicate_1Activity at 0.031 uM-Replicate_1Activity at 0.068 uM-Replicate_1Activity at 0.153 uM-Replicate_1Activity at 0.342 uM-Replicate_1Activity at 0.763 uM-Replicate_1Activity at 1.702 uM-Replicate_1Activity at 3.794 uM-Replicate_1Activity at 8.468 uM-Replicate_1Activity at 18.17 uM-Replicate_1Activity at 32.48 uM-Replicate_1Activity at 70.35 uM-Replicate_1Activity at 94.96 uM-Replicate_1Activity at 260.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive0413.0889-1.66864.478718.6854-0.48264.7953-0.59428.07730.92478.9629-2.196715.345715.139216.4786.722113.0889QC'd by NCIInactive0
Cytotoxic13.333236.732221Complete curve; partial efficacy-4.87514.95490.7923-29.6627.0702-1.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-31.14381.479820.25985.08754.60124.75079.9862-3.20264.47916.0258-0.530311.199220.09346.1387-29.52-31.1438QC'd by NCICytotoxic21.1317103.350741Partial curve; high efficacy-4.67511.86170.9757-102.1811
Inactive040.4471-2.8001-1.7403-1.12262.98012.11316.665210.218212.80795.8803-0.2215-10.6114-1.02321.931912.73780.4471QC'd by NCIInactive0
Cytotoxic29.849391.037120Single point of activity-4.52514.95490.971-90.40840.6287-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-81.49860.17360.6935-1.3312-0.206112.2146-4.40990.0668-1.3756-0.3616-1.11661.2081-0.25880.0225-8.4892-81.4986QC'd by SigmaAldrichCytotoxic29.849396.057440Partial curve; high efficacy-4.52514.0950.9745-98.4887
Cytotoxic29.849343.259620Partial curve; partial efficacy; poor fit-4.52512.58840.654-43.934-0.6743-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-33.54971.51315.83030.6388-4.89485.5838-6.034-5.42513.19371.27950.2248-7.0642-13.9432-0.3387-11.983-33.5497QC'd by NCICytotoxic23.710154.80320Partial curve; partial efficacy-4.62513.06540.9118-56.0531
Inactive03.990.463312-3.545940 0 0 0 0 0 0 0 0 0 0 0 0 0 1-5.1224-1.1431-0.4077-9.2962-6.7439-1.3041-5.108-0.428-0.48521.6732-2.7718-12.1216-1.7511-0.57919.852-5.1224QC'd by NCIInactive0
Inactive048.2451-2.30262.27657.3956-4.68135.92238.448911.15386.86045.9576.8113.9931-7.5923-6.506313.20258.2451QC'd by NCIInactive0
Inactive047.8779-11.401-0.64871.58362.34767.156-6.7357-11.41271.6491-7.1693-11.7901-8.769-6.8463-0.06161.77097.8779QC'd by NCIInactive04.95490.57718
Cytotoxic29.849357.823420Single point of activity-4.52514.95490.8931-57.47810.3453-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-51.2317-1.15572.6188-7.7075-0.359.48620.1230.66930.6672-2.0531-1.7983-5.341910.3150.1178-7.6014-51.2317QC'd by NCICytotoxic26.603247.886120Partial curve; partial efficacy-4.57513.1320.946-50.222
Inactive04-2.258415.0081.8981-5.02357.271710.479510.62950.407-2.5232-2.4835-0.74710.0879-1.3303-2.762810.6838-2.2584QC'd by LabotestInactive0
Inactive04.44950.4193-2.29222.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.9246-0.8801-0.53812.6488-0.05617.27753.7735.28930.09192.13935.6234-1.8779-4.8269-1.53031.2059-3.9246QC'd by NCIInactive03.92950.6224-26.8855
Inactive044.84140.39352.1814-15.55856.1583-2.7506-1.29682.408-3.1984-19.027510.67640.856914.6462-2.9317-22.00254.8414QC'd by NCIInactive0
Inactive04-3.117-2.9332-1.54190.48350.1637-4.1579-1.392-1.1741-1.09652.2022-5.70182.53112.8257-1.2786-0.6983-3.117QC'd by NCIInactive0
Cytotoxic29.849370.737440Partial curve; high efficacy-4.52514.95490.9648-74.0453-3.3079-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-66.7044-0.8515-0.6476-6.75680.34160.33811.3744-2.6166-7.5972-0.9959-6.0997-2.5425-6.0215-8.4358-12.6041-66.7044QC'd by NCICytotoxic29.849394.666240Partial curve; high efficacy-4.52514.95490.9892-97.0028
Inactive01.10.33837-5.697440 0 0 0 0 0 0 0 0 0 0 0 0 0 07.3431-6.3907-4.9726-7.29748.7208-13.9145-5.2667-5.7344-12.4941-5.56985.73531.1859-7.230414.63531.82357.3431QC'd by NCIInactive00.90.589217
Inactive045.737312.5288-1.0974-2.79388.27274.0907-1.41678.99574.80517.5768-1.30747.23573.08392.88293.96365.7373QC'd by NCIInactive03.19250.4553-4.6844
Inactive044.5023.9295-8.0465-3.62329.46645.37291.138612.185-3.65222.981114.46385.46410.06047.6392-5.06044.502QC'd by NCIInactive0
Inactive04-1.9982-3.6344-4.6559-0.3788-2.1166-1.2585-1.98810.0232-0.9085-1.1425-5.0225-1.24591.0659-5.4568-3.298-1.9982QC'd by ChembridgeInconclusive26.603228.322310Partial curve; partial efficacy; poor fit-4.57512.09370.871525.5
Inactive04-16.5603-2.74410.3192.3141-0.1723-19.45910.0669-17.7681-2.4009-3.26419.5003-3.13731.90082.00541.7817-16.5603QC'd by NCICytotoxic33.491536.815220Partial curve; partial efficacy; poor fit-4.47514.95490.7907-33.8152
Inactive04-9.10111.67360.31128.9066.348410.2071-6.926413.5429-4.395717.17929.543-14.114110.7621-0.2142-14.2769-9.1011QC'd by NCIInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.77120.05930.0635-0.0984-0.218-0.7712QC'd by "Prestwick Chemical; Inc."0
Inactive040.28480.45950.13770.23990.45920.2848QC'd by "Prestwick Chemical; Inc."0
Inactive040.10910.08720.002-0.128-0.01040.1091QC'd by "Prestwick Chemical; Inc."0
Inactive040.35690.44360.30790.14920.38140.3569QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4718-0.21590.1141-0.2538-0.4782-0.4718QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.7519-0.0052-0.0382-0.3499-0.5531-0.7519QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3026-0.176-0.2919-0.2217-0.1667-0.3026QC'd by "Prestwick Chemical; Inc."0
Inactive040.00260.10340.01420.20370.21520.0026QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.309-0.54610.3903-0.3625-0.0293-0.309QC'd by "Prestwick Chemical; Inc."0
Inactive040.1015-0.23980.08980.41030.37930.1015QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.02650.19180.1501-0.07350.0724-0.0265QC'd by "Prestwick Chemical; Inc."0
Inactive040.3519-0.54170.1370.20740.37870.3519QC'd by "Prestwick Chemical; Inc."0
Inactive040.11140.07490.32080.3560.48040.1114QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.45320.0227-0.0204-0.4367-0.3391-0.4532QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.4937-0.7632-0.0181-0.4913-0.1598-0.4937QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.2868-0.3361-0.3349-0.465-0.3474-0.2868QC'd by "Prestwick Chemical; Inc."0
Inactive040.33880.03910.14580.56180.08170.3388QC'd by "Prestwick Chemical; Inc."0
Inactive040.5747-0.55850.02420.36260.57350.5747QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.3048-0.2054-0.3202-0.3697-0.1434-0.3048QC'd by "Prestwick Chemical; Inc."0
Inactive04-0.27210.25420.1392-0.3556-0.4304-0.2721QC'd by "Prestwick Chemical; Inc."0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC478CG
Protocol: Tox21 Assay Protocol Summary:

2,000 HepG2 cells in 5 uL of culture medium (MEM containing 10% FBS) per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (ThermoFisher Scientific, Waltham, MA). The assay plates were incubated overnight at 37 C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys , San Diego, CA). After the assay plates were incubated for 1 hr at 37 C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590 nm respectively.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0029-0.0082-0.00260.13990.0699-0.0029QC'd by "SIGMA"0
Inactive04-0.10090.004-0.1385-0.05520.0167-0.1009QC'd by "ChromaDex"0
Inactive04-0.00270.04690.0106-0.0323-0.0264-0.0027QC'd by "SIGMA"0
Inactive040.0680.04520.00930.1349-0.05650.068QC'd by "SigmaAldrich"0
Inactive04-0.01020.00830.0497-0.0368-0.1188-0.0102QC'd by "Sensient"0
Inactive040.16110.01260.0217-0.06560.10580.1611QC'd by "Pfaltz-Bauer"0
Inactive040.01860.00820.0242-0.11250.1760.0186QC'd by "SigmaAldrich"0
Inactive040.0141-0.0188-0.03030.00210.09840.0141QC'd by "SigmaAldrich"0
Inactive04-0.06960.0137-0.0094-0.0575-0.0122-0.0696QC'd by "SigmaAldrich"0
Inactive04-0.0879-0.00670.1326-0.0156-0.0041-0.0879QC'd by "SigmaAldrich"0
Inactive040.0162-0.0159-0.0079-0.01810.08710.0162QC'd by "SigmaAldrich"0
Inactive040.02930.0807-0.0391-0.1788-0.09160.0293QC'd by "SIGMA"0
Inactive04-0.0528-0.0224-0.08430.0049-0.0082-0.0528QC'd by "SIGMA"0
Inactive040.11520.05240.1778-0.0592-0.05560.1152QC'd by "SIGMA"0
Inactive04-0.03240.04210.01430.01780.0302-0.0324QC'd by "SIGMA"0
Inactive04-0.1527-0.0095-0.1287-0.0855-0.0912-0.1527QC'd by "SIGMA"0
Inactive040.1560.0209-0.00190.010.00660.156QC'd by "SIGMA"0
Inactive040.0052-0.00170.0141-0.07196.0E-40.0052QC'd by "SIGMA"0
Inactive04-0.0288-0.0779-0.0066-0.0587-0.0039-0.0288QC'd by "SIGMA"0
Inactive04-0.0014-0.08470.0444-0.017-0.0041-0.0014QC'd by "SigmaAldrich"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CB
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.0993-0.0315-0.0456-0.0314-0.0445-0.0993QC'd by "SIGMA"0
Inactive04-0.0413-0.330.9732-0.1408-0.2626-0.0413QC'd by "SIGMA"0
Inactive043.0E-4-0.0951-0.0908-0.0608-0.01023.0E-4QC'd by "SIGMA"0
Inactive040.00362.0E-4-0.1154-0.1852-0.02580.0036QC'd by "SIGMA"0
Inactive04-0.08410.02920.0072-0.0606-0.0747-0.0841QC'd by "SIGMA"0
Inactive04-0.0562-0.02190.0027-0.0792-0.1435-0.0562QC'd by "SIGMA"0
Inactive04-0.0228-0.2225-0.17238.0E-4-0.2899-0.0228QC'd by "SIGMA"0
Inactive04-0.10910.0012-0.0968-0.007-0.2223-0.1091QC'd by "SIGMA"0
Inactive04-0.03890.07040.0162-0.0035-0.0387-0.0389QC'd by "SIGMA"0
Inactive040.0777-0.1888-0.0421-0.0179-0.13070.0777QC'd by "SIGMA"0
Inactive04-0.1076-0.1771-0.0039-0.04160.0041-0.1076QC'd by "SIGMA"0
Inactive04-0.0441-0.05340.0039-0.0433-0.1015-0.0441QC'd by "TCI"0
Inactive04-0.42250.18470.0082-0.0822-0.0703-0.4225QC'd by "SIGMA"0
Inactive040.0630.0914-0.00420.0899-0.04430.063QC'd by "SIGMA"0
Inactive040.21370.17290.0260.23310.10530.2137QC'd by "SIGMA"0
Inactive04-0.0274-0.01920.12090.04090.0156-0.0274QC'd by "SIGMA"0
Inactive040.0634-0.01480.0720.08030.08560.0634QC'd by "SIGMA"0
Inactive040.0335-0.04990.1012-0.00170.26310.0335QC'd by "SIGMA"0
Inactive04-0.0334-0.0211-0.0049-0.03310.19-0.0334QC'd by "SIGMA"0
Inactive040.15920.01470.11910.10190.12680.1592QC'd by "SIGMA"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: SPEC167CR
Protocol: Tox21 Assay Protocol Summary:

2,000 HEK293 cells in 5 uL of culture medium containing 10% dialyzed FBS per well were dispensed into black wall/clear bottom 1536-well plates using a Multidrop Combi Dispenser (Thermo Scientific). The assay plates were incubated for 4-5 hr at 37C to allow cell attachment to the well bottom, followed by the transfer of 23 nL compound or DMSO vehicle by a pintool work station (Kalypsys, San Diego, CA). After the assay plates were incubated overnight at 37C and 5% CO2, fluorescence intensities in the assay plates were measured by an Envision (PerkinElmer, Shelton, CT) plate reader using three labels for measuring blue, green and red fluorescence at excitations 460, 535 and 590nm respectively.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0005530000 uM-Replicate_1Activity at 0.00276 uM-Replicate_1Activity at 0.00765 uM-Replicate_1Activity at 0.012 uM-Replicate_1Activity at 0.024 uM-Replicate_1Activity at 0.034 uM-Replicate_1Activity at 0.074 uM-Replicate_1Activity at 0.148 uM-Replicate_1Activity at 0.199 uM-Replicate_1Activity at 0.370 uM-Replicate_1Activity at 0.743 uM-Replicate_1Activity at 1.207 uM-Replicate_1Activity at 1.859 uM-Replicate_1Activity at 3.722 uM-Replicate_1Activity at 9.170 uM-Replicate_1Activity at 13.42 uM-Replicate_1Activity at 18.62 uM-Replicate_1Activity at 45.97 uM-Replicate_1Activity at 91.34 uM-Replicate_1Activity at 95.67 uM-Replicate_1Activity at 202.9 uM-Replicate_1Activity at 354.0 uM-Replicate_1Activity at 920.3 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2Fit_ZeroActivity-Replicate_2Fit_CurveClass-Replicate_2
Inactive04-0.1742-0.0105-0.0707-0.708-0.8608-0.1742QC'd by "NCI"0
Inactive04-0.15950.087-0.0389-0.0424-0.0089-0.1595QC'd by "NCI"0
Inactive040.17150.56230.2590.06620.03240.1715QC'd by "NCI"0
Inactive040.04060.1038-4.0E-40.08940.12640.0406QC'd by "SigmaAldrich"0
Inactive040.439-0.1165-0.2370.53740.0650.439QC'd by "NCI"0
Inactive04-0.1787-0.0681-0.0763-0.05880.0674-0.1787QC'd by "NCI"0
Inactive04-0.26880.03020.2349-0.1201-0.1287-0.2688QC'd by "NCI"0
Inactive04-0.1086-0.2195-0.0573-0.14660.1358-0.1086QC'd by "NCI"0
Inactive04-0.1833-0.03-0.0379-0.4701-0.1431-0.1833QC'd by "NCI"0
Inactive04-0.9523-1.1611-0.9118-1.0013-1.0781-0.9523QC'd by "Labotest"0
Inactive04-0.2307-0.10680.4032-0.0433-0.0679-0.2307QC'd by "NCI"0
Inactive040.06170.30390.1775-0.00510.08570.0617QC'd by "NCI"0
Inactive04-0.1350.1614-0.083-0.1721-0.0432-0.135QC'd by "NCI"0
Inactive040.2214-0.6929-0.11650.0685-0.05560.2214QC'd by "NCI"0
Inactive04-0.2027-0.05290.0564-0.9701-0.3154-0.2027QC'd by "NCI"0
Inactive040.06990.0444-0.03810.03760.19960.0699QC'd by "NCI"0
Inactive040.0459-0.04550.12930.11980.02850.0459QC'd by "NCI"0
Inactive04-0.0306-0.0309-0.01430.02940.0175-0.0306QC'd by "Chembridge"0
Inactive04-0.02680.23620.2368-0.0791-0.0097-0.0268QC'd by "NCI"0
Inactive040.0114-0.9843-0.7454-0.13590.21030.0114QC'd by "NCI"0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatotoxicity
External ID: CHEMBL1697799
Protocol: N/A
Comment: Journal: Curr Drug Discov Technol
Year: 2004
Volume: 1
Issue: 4
First Page: 243
Last Page: 254
DOI: 10.2174/1570163043334794

Target ChEMBL ID: CHEMBL1697861
ChEMBL Target Name: Hepatotoxicity
ChEMBL Target Type: PHENOTYPE - Target is a biological phenotype or process
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueActivity Comment
SGOT Increase - Index ValueData Not Available
SGOT Increase - Number of ReportsData Not Available
SGOT Increase - Activity ScoreData Not Available
SGOT Increase - Activity ScoreInactive
SGOT Increase - Index Value=0.6
SGOT Increase - Number of Reports<4
SGOT Increase - Activity ScoreInactive
SGOT Increase - Index Value=1.9
SGOT Increase - Number of Reports>=4
SGOT Increase - Activity ScoreMarginally Active
SGOT Increase - Index Value=3.8
SGOT Increase - Number of Reports>=4
SGOT Increase - Activity ScoreMarginally Active
SGOT Increase - Index Value=3.1
SGOT Increase - Number of Reports>=4
SGOT Increase - Activity ScoreActive
SGOT Increase - Number of Reports>=4
SGOT Increase - Index Value=5.6
SGOT Increase - Activity ScoreInactive
SGOT Increase - Index Value=1
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatotoxicity
External ID: CHEMBL1697800
Protocol: N/A
Comment: Journal: Curr Drug Discov Technol
Year: 2004
Volume: 1
Issue: 4
First Page: 243
Last Page: 254
DOI: 10.2174/1570163043334794

Target ChEMBL ID: CHEMBL1697861
ChEMBL Target Name: Hepatotoxicity
ChEMBL Target Type: PHENOTYPE - Target is a biological phenotype or process
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueActivity Comment
SGPT Increase - Index ValueData Not Available
SGPT Increase - Number of ReportsData Not Available
SGPT Increase - Activity ScoreData Not Available
SGPT Increase - Activity ScoreInactive
SGPT Increase - Index Value=0.6
SGPT Increase - Number of Reports<4
SGPT Increase - Activity ScoreInactive
SGPT Increase - Index Value=2.1
SGPT Increase - Number of Reports>=4
SGPT Increase - Index ValueData Not Available
SGPT Increase - Number of ReportsData Not Available
SGPT Increase - Activity ScoreData Not Available
SGPT Increase - Activity ScoreInactive
SGPT Increase - Index Value=2.1
SGPT Increase - Number of Reports>=4
SGPT Increase - Activity ScoreMarginally Active
SGPT Increase - Index Value=3
SGPT Increase - Number of Reports>=4
SGPT Increase - Activity ScoreInactive
SGPT Increase - Index Value=0.5
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatotoxicity
External ID: CHEMBL1697801
Protocol: N/A
Comment: Journal: Curr Drug Discov Technol
Year: 2004
Volume: 1
Issue: 4
First Page: 243
Last Page: 254
DOI: 10.2174/1570163043334794

Target ChEMBL ID: CHEMBL1697861
ChEMBL Target Name: Hepatotoxicity
ChEMBL Target Type: PHENOTYPE - Target is a biological phenotype or process
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueActivity Comment
LDH Increase - Index ValueData Not Available
LDH Increase - Number of ReportsData Not Available
LDH Increase - Activity ScoreData Not Available
LDH Increase - Activity ScoreInactive
LDH Increase - Index Value=0.9
LDH Increase - Number of Reports<4
LDH Increase - Activity ScoreInactive
LDH Increase - Index Value=1.2
LDH Increase - Number of Reports>=4
LDH Increase - Index ValueData Not Available
LDH Increase - Number of ReportsData Not Available
LDH Increase - Activity ScoreData Not Available
LDH Increase - Activity ScoreInactive
LDH Increase - Index Value=0.9
LDH Increase - Number of Reports>=4
LDH Increase - Activity ScoreMarginally Active
LDH Increase - Index Value=3.7
LDH Increase - Number of Reports>=4
LDH Increase - Activity ScoreInactive
LDH Increase - Index Value=0.5
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatotoxicity
External ID: CHEMBL1697802
Protocol: N/A
Comment: Journal: Curr Drug Discov Technol
Year: 2004
Volume: 1
Issue: 4
First Page: 243
Last Page: 254
DOI: 10.2174/1570163043334794

Target ChEMBL ID: CHEMBL1697861
ChEMBL Target Name: Hepatotoxicity
ChEMBL Target Type: PHENOTYPE - Target is a biological phenotype or process
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueActivity Comment
GGT Increase - Index ValueData Not Available
GGT Increase - Number of ReportsData Not Available
GGT Increase - Activity ScoreData Not Available
GGT Increase - Activity ScoreInactive
GGT Increase - Index Value=0.3
GGT Increase - Number of Reports<4
GGT Increase - Activity ScoreInactive
GGT Increase - Index Value=0.5
GGT Increase - Number of Reports<4
GGT Increase - Index ValueData Not Available
GGT Increase - Number of ReportsData Not Available
GGT Increase - Activity ScoreData Not Available
GGT Increase - Activity ScoreInactive
GGT Increase - Index Value=0.8
GGT Increase - Number of Reports>=4
GGT Increase - Activity ScoreInactive
GGT Increase - Index Value=0
GGT Increase - Number of Reports<4
GGT Increase - Activity ScoreInactive
GGT Increase - Index Value=0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Phospholipidosis
External ID: CHEMBL1697855
Protocol: N/A
Comment: Journal: Toxicol Mech Methods
Year: 2008
Volume: 18
Issue: 2
First Page: 217
Last Page: 227
DOI: 10.1080/15376510701857262

Target ChEMBL ID: CHEMBL1626541
ChEMBL Target Name: Phospholipidosis
ChEMBL Target Type: PHENOTYPE - Target is a biological phenotype or process
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeActivity Comment
PhospholipidosisNegative: confirmed by electron microscopy
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
PhospholipidosisPositive: weak inducer based on presence of foamy macrophages and cytoplasmic vacuolations
PhospholipidosisPositive: weak inducer based on presence of foamy macrophages and cytoplasmic vacuolations
PhospholipidosisPositive: strong inducer confirmed by electron microscopy
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
PhospholipidosisNegative: confirmed by electron microscopy
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
PhospholipidosisPositive: strong inducer confirmed by electron microscopy
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
PhospholipidosisPositive: weak inducer based on presence of foamy macrophages and cytoplasmic vacuolations
PhospholipidosisPositive: weak inducer based on presence of foamy macrophages and cytoplasmic vacuolations
PhospholipidosisNegative: confirmed by electron microscopy
PhospholipidosisPositive: weak inducer based on presence of foamy macrophages and cytoplasmic vacuolations
PhospholipidosisNegative: confirmed by electron microscopy
PhospholipidosisNegative: based on the absence of positive reported data from WMDD
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRA481
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/6 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514703 uM-Replicate_1W460-Activity at 0.0001157795 uM-Replicate_1W460-Activity at 0.0002347639 uM-Replicate_1W460-Activity at 0.0005064679 uM-Replicate_1W460-Activity at 0.00101 uM-Replicate_1W460-Activity at 0.00226 uM-Replicate_1W460-Activity at 0.00505 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.056 uM-Replicate_1W460-Activity at 0.125 uM-Replicate_1W460-Activity at 0.280 uM-Replicate_1W460-Activity at 0.624 uM-Replicate_1W460-Activity at 1.391 uM-Replicate_1W460-Activity at 3.095 uM-Replicate_1W460-Activity at 6.900 uM-Replicate_1W460-Activity at 15.01 uM-Replicate_1W460-Activity at 29.18 uM-Replicate_1W460-Activity at 62.39 uM-Replicate_1W460-Activity at 79.15 uM-Replicate_1W460-Activity at 213.3 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive040.7562-2.0191-2.8763-0.9026-3.551-0.7809-0.2770.3016-2.05597.6695-0.4571-0.4785-0.3067-3.19312.29950.7562102.72020.5091-13.21010.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.8015
Inconclusive2.683243.355504.95490.33697-1.259840 0 0 0 0 0 0 0 0 0 0 0 0 0 05.13651.0101-0.5652-4.3951-0.2458-3.9615-0.72250.0703-5.2165-4.71332.5855-0.82580.39810.8412-1.08125.1365103.06540.430911-0.15540 0 0 0 0 0 0 0 0 0 0 0 0 0 010.4779
Inactive00.9310.515-2.2498140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.19170.0432-0.94582.66191.9187-0.00912.6540.7197-0.8071-0.0436-0.1456-2.86940.2333-3.1248-1.627-2.19171040.5349
Cytotoxic23.914564.59580Partial curve; partial efficacy-4.72133.1320.9596-43.45790.2745-2.20 0 0 0 0 0 0 0 0 0 0 0 0 0 0-39.3622.89331.82591.0907-0.1463-0.10590.92180.09150.19131.3078-6.7647-0.7119-0.62320.4675-17.992-39.362100.30.5041-9.1529140 0 0 0 0 0 0 0 0 0 0 0 0 0 13.6116
Inactive00.50.455-21.31571.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.42971.0157-1.7522.7232.69846.869-3.71430.19816.1321-2.0281-8.9254-4.3551-0.3757-5.1288-2.2826-14.4297100.20.470911.5-5.046140 0 0 0 0 0 0 0 0 0 0 0 0 0 1-2.922
Inconclusive15.08948.866903.51170.44866.5-1.011940 0 0 0 0 0 0 0 0 0 0 0 0 0 05.50351.07060.905-0.25830.69930.4392-0.1511-3.58922.2605-4.5752-0.49010.3402-2.2626-5.42666.35045.5035103.1320.5006-12.72791.540 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.019
Activator0.095244.78110Single point of activity-7.02134.95490.971588.6934-1.347630 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.2744-4.73250.61890.21280.81980.5686-0.35281.205386.9543-3.9984-3.1116-0.3361-4.4875-4.0498-7.4011-0.27440Single point of activity-7.02134.95490.969543.878-0.903130 0 0 0 0 0 0 0 1 1 1 1 1 1 1-0.1232
Inactive043.93180.3895-0.21130.182-0.9258-0.4412-3.95122.1721-0.1688-5.0997-0.15442.3995-4.165-0.19191.89093.9318104-1.6204
Inactive04.95490.4549-2.1971140 0 0 0 0 0 0 0 0 0 0 0 0 0 10.39480.2258-0.38513.3271.6718-0.0652.57751.6671-0.09210.011-0.24882.0368-2.0108-3.4976-0.2290.3948103.51170.49812-0.310640 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.5444
Inactive04.95490.49990.779540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.19890.56481.7838-0.99043.56074.2105-1.85041.559-0.7889-0.57311.13450.3821.1458-0.6344-0.05567.19891043.2539
Inconclusive26.832542.156903.1320.6237-18.228140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-14.8509-0.43261.3737-0.723-1.5954-0.98793.3248-0.25092.6333-1.3551-3.191.65445.081210.7255-16.44-14.85090Complete curve; partial efficacy; poor fit-5.32134.95490.903616-1.39761.40 0 0 0 0 0 0 0 0 0 0 0 0 1 014.2731
Inactive01.3310.44069-1.315540 0 0 0 0 0 0 0 0 0 0 0 0 0 07.7682-8.1796-1.2864-0.92690.0489-1.1023.6629-5.3855-2.0892-3.4173.63520.2376-0.11450.36824.02527.7682104.0950.645512.50.056140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.4789
Inactive04-1.77665.9446-8.071110.9483-0.66150.7628-0.19420.81740.424-0.04970.3107-1.4675-4.3278-0.9634-3.4067-1.77661040.3915
Cytotoxic30.106580.09980Single point of activity-4.57134.95490.9233-34.1878-1-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.15651.4442-1.42590.5602-0.5727-1.5149-1.1531-1.7711-0.5991-1.6507-0.5856-0.7334-2.4262-6.8854-0.1814-30.15650Single point of activity-4.57134.95490.964133.76670.413730 0 0 0 0 0 0 0 0 0 0 0 0 0 0123.858
Inactive04.0950.6978-0.5-7.11540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-0.8355-7.1792-4.2685-1.14751.1488-2.8672-0.65330.9563-0.5809-0.63290.28570.6351.0765-3.2022-0.934-0.8355104.95490.8946-0.469515.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.4115
Inactive047.6683-0.213812.7411-0.95732.68175.82062.76031.9502-1.1272.6603-0.154-4.84897.2899-0.02820.21517.6683100.70.4452-6.3234340 0 0 0 0 0 0 0 0 0 0 0 0 0 1-1.9779
Inactive04.95490.38580-3.382540 0 0 0 0 0 0 0 0 0 0 0 0 0 00.3426-2.7245-4.1769-2.5201-5.3186-0.55251.2952-5.152-6.9854-0.68020.87571.22690.5227-3.0321.11160.3426104-1.3858
Inactive043.5373-0.4222-4.6002-0.5607-0.0671-0.45211.69491.7648-0.6170.1086-4.2139-4.41190.48912.0611-0.44833.5373104-0.2942
Activator10.682283.89470Single point of activity-4.97133.92950.884675.0549-2.701730 0 0 0 0 0 0 0 0 0 0 0 0 0 10.7587-0.7027-0.0356-2.9874-6.5873-2.95230.4426-0.8132-2.168-2.9385-0.9678-1.866-0.243-1.378889.35110.75870Single point of activity-4.97133.990.888280.6868-3.207930 0 0 0 0 0 0 0 0 0 0 0 0 0 10.0157
Inactive043.2274-0.4217-5.36674.2879-0.76117.993-0.6172-2.95230.12040.2389-2.49690.367-2.94147.0059-0.88663.2274103.06540.600216-1.455840 0 0 0 0 0 0 0 0 0 0 0 0 0 15.6692
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: 1011189
Protocol:
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00737 uMActivity at 0.034 uMActivity at 0.074 uMActivity at 0.160 uMActivity at 0.236 uMActivity at 0.363 uMActivity at 0.672 uMActivity at 0.802 uMActivity at 1.176 uMActivity at 1.813 uMActivity at 3.626 uMActivity at 4.165 uMActivity at 5.886 uMActivity at 9.068 uMActivity at 18.22 uMActivity at 21.24 uMActivity at 33.77 uMActivity at 45.94 uMActivity at 91.56 uMActivity at 107.6 uMActivity at 194.3 uMActivity at 231.0 uMActivity at 0.159 uMActivity at 0.360 uMActivity at 0.847 uMActivity at 1.840 uMActivity at 9.105 uMActivity at 21.25 uMActivity at 45.98 uMActivity at 107.7 uMActivity at 0.0002950000 uMActivity at 0.00135 uMActivity at 0.00295 uMActivity at 0.00640 uMActivity at 0.00942 uMActivity at 0.014 uM
Inactive26.025701.78850.999712.5-13.525740 0 0 0 1-16.4169-13.3547-10.0454.879911.8869-16.4169
Inhibitor11.220268.575810Single point of activity-4.954.0950.9841-51.897616.6782-30 0 0 0 0-51.769712.507722.751815.0653-4.0088-51.7697
Inhibitor7.0795112.066143Partial curve; high efficacy-5.151.88510.9823-103.18038.8859-2.10 0 0 0-95.53733.23779.0024-65.3012-95.5373
Inhibitor15.8489105.509342Partial curve; high efficacy-4.810.9579-114.0492-8.5398-2.10 0 0 0 0-90.5152-4.0803-11.1572-29.099-39.1247-90.5152
Inactive16.477501.3310.9615-2.5103-18.987941 0 0 0 0 0 1-16.3315-65.7135-14.9899
Inhibitor7.0795101.797683Complete curve; high efficacy-5.154.95490.9565-95.44826.3494-1.10 0 0 0 0-94.451620.9917-9.24498.049-74.805-94.4516
Inactive12.307103.06540.5785-22.7235-10.416540 0 0 0 0-26.853-10.7637-15.6935-26.1694-15.1194-26.853
Inhibitor0.089112.386510Complete curve; partial efficacy; poor fit-7.054.95490.364-34.6437-22.2572-1.40 0 0 0 0-37.9759-25.631-39.7031-25.7241-35.5044-37.9759
Inactive10.026404.44950.7108-12.3905-2.364140 0 0 0 1-7.3774-6.9326-0.3034-11.4012-11.9921-7.3774
Inactive29.146503.06540.67871.473-27.673640 0 0 0 0 0 1-21.724-27.2731-11.0127
Inactive25.21704.95490.4619-13.2171240 0 0 0 0-8.30867.9877-27.6808-0.1174-16.8896-8.3086
Inactive12.838204.95490.3995-3.393-16.231240 0 0 0 1-15.3571-15.1609-13.0051-20.6093-11.1608-15.3571
Inhibitor35.481326.237210Partial curve; partial efficacy; poor fit-4.454.95490.6657-53.1099-26.8727-2.40 0 0 0 0-47.5916-28.5919-36.8323-19.4772-23.3034-47.5916
Inactive7.543804.95490.8451-6.8775-14.421240 0 0 0 0-6.4743-14.3323-14.5177-4.8979-9.6517-6.4743
Inactive37.81404.95490.7329-20.885116.928840 0 0 0 0 0 1-3.613.1204-26.6275
Inactive13.166504.95490.6781-12.166540 0 0 0 00.861-4.7712-15.0697-16.8054-1.02860.861
Inactive6.235504.95490.32441-5.235540 0 0 0 02.3165-3.52964.2330.0986-3.45432.3165
Inactive15.475304.95490.9575-17.3357-1.860541 0 0 0 0-15.6395-25.4707-3.6337-19.0298-16.8468-15.6395
Inactive14.093800.90.9644-15.4586-1.364840 0 0 0 1-6.1352-1.1373-3.7059-5.1536-11.2155-6.1352
Inactive04-19.0793-27.1382-31.3978
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:The Scripps Research Institute Molecular Screening Center 靶标:N/A
External ID: FBW7_ACT_ALPHA_1536_1X%ACT PRUN
Protocol: Assay Overview:
FBW7 assay principle. In this assay, either mutant or wild type (w.t.) FBW7 interact with phosphorylated cyclin E peptide (cycE~P), which will bring donor and acceptor beads into close proximity. Laser excitation of the donor beads converts oxygen to an excited singlet state. Reaction of the singlet oxygen with the acceptor beads further activates a chemiluminescence/fluorescence reaction within the same bead resulting in emitted light at 520-620 nm. Small molecule activators that enhance the mutant FBW7 interaction with the cycE~P decrease the distance of the acceptor beads, thus leading to increased signal being emitted signal.
Protocol Summary:
There are six steps in this 1536 well assay format which are listed in order. First, 2.5uL/well of a 2X working solution containing RLFbw7 [12.5nM final], Cyclin E peptide [12.5nM final], and Ni beads [5ug/mL final], in assay buffer (25mM Tris-HCl pH 7.4 + 100mM NaCl, 0.1% Tween-20, 5mM ?-Mercaptoethanol and 0.05% BSA) was dispensed into columns 1-44. Then 2.5uL/well of a 2X working solution containing WTFbw7 [12.5nM final], Cyclin E peptide [12.5nM final], and Ni beads [5ug/mL final], in assay buffer was dispensed into columns 45-48. Using the pintool transfer device 134nL of compound or control was added to each well. This achieved a nominal screening concentration of 26.1uM and 2.6% DMSO concentration. This was followed by the addition of SA beads to all wells at 5ug/mL final concentration in assay buffer. The assay was then incubated for 20 hours in a temperature controlled 25C environment followed by Alphascreen detection using the PerkinElmer EnVision.

The percent activation for each compound was calculated as follows:

100 *( ( Test_Compound - Median_Low_Control ) / ( Median_High_Control - Median_Low_Control ) )
Where:
Test_Compound is defined as wells containing RLFbw7 (mutant), cyclin E peptide and Nickel acceptor beads in the presence of test compound
High_Control is defined as wells containing WTFbw7 (wild type), cyclin E peptide and Nickel acceptor beads
Low_Control is defined as the median of the wells containing DMSO, RLFbw7 (mutant), cyclin E peptide and Nickel acceptor beads
PubChem Activity Outcome and Score:

A mathematical algorithm was used to determine active compounds. Two values were calculated: (1) the average percent activation of all compounds tested for the screen, and (2) three times their standard deviation. The sum of these two values was used as a cutoff parameter, i.e. any compound that exhibited greater percent activation than the cutoff parameter (1.85% in the case here) was declared active.
The reported PubChem Activity Score has been normalized to 100% observed primary inhibition. Negative % inhibition values are reported as activity score zero.
The activity score range for active compounds is 100-1, for inactive 1-0.
List of Reagents:
Ni Beads- PerkinEmer Lifesciences Cat#6760619R
RLFbw7-Assay Provider
WTFbw7-Assay Provider
Cyclin E peptide-Assay Provider
5M NaCl- Sigma Cat# S6546-1L
Tween20- Fisher Cat# BP337
Tris 1M pH7.4 Research Organics Cat# 9686T
BSA-Sigma Cat#A7030
?-Mercaptoethanol-SigmaM6250
1536-well plates (Corning, part 7254)
Comment: Due to the size of the Scripps Molecular Screening Center compound library, this assay may have been run as two or more separate campaigns, each campaign testing a unique set of compounds. All data reported were normalized on a per-plate basis. Possible artifacts of this assay can include, but are not limited to: dust or lint located in or on wells of the microtiter plate, compounds that modulate well fluorescence. All test compound concentrations reported above and below are nominal; the specific test concentration(s) for a particular compound may vary based upon the actual sample provided by the Scripps Molecular Screening Center.
Inhibition at 26.1 uM
1.22
1.22
1.22
1.22
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
1.21
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: PPARGA972
Protocol: Tox21 Assay Protocol Summary:

PPARg-bla cells were dispensed at 3000 cells/6uL/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at 37C and 5% CO2 for 5 h, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a Pintool station (Kalypsys, San Diego, CA). The assay plates were incubated at 37C for 17 h. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Bioraptr Flying Reagent Dispenser (FRD) workstation (Beckman Coulter, Indianapolis, IN, USA), the plates were incubated at room temperature for 1 h, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514202 uM-Replicate_1W460-Activity at 0.0001156673 uM-Replicate_1W460-Activity at 0.0002222558 uM-Replicate_1W460-Activity at 0.0004931235 uM-Replicate_1W460-Activity at 0.00104 uM-Replicate_1W460-Activity at 0.00231 uM-Replicate_1W460-Activity at 0.00516 uM-Replicate_1W460-Activity at 0.012 uM-Replicate_1W460-Activity at 0.026 uM-Replicate_1W460-Activity at 0.058 uM-Replicate_1W460-Activity at 0.129 uM-Replicate_1W460-Activity at 0.288 uM-Replicate_1W460-Activity at 0.642 uM-Replicate_1W460-Activity at 1.434 uM-Replicate_1W460-Activity at 3.198 uM-Replicate_1W460-Activity at 7.140 uM-Replicate_1W460-Activity at 15.11 uM-Replicate_1W460-Activity at 25.00 uM-Replicate_1W460-Activity at 54.78 uM-Replicate_1W460-Activity at 78.95 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036788 uM-Replicate_1
Inactive045.42281.8804-1.53680.6322-0.2357-0.44520.7975-0.3858-1.01032.282-1.42024.9509-0.30931.48620.40195.4228104.95490.35122-1.451740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.1576
Inactive045.82145.22420.64251.8288-0.8085-5.16881.092210.98658.48039.20855.59025.4150.62772.64660.9385.8214104-1.1424
Inactive04-2.30724.5751-0.75450.930925.8242-2.107216.09821.02894.92540.437312.04393.5090.3752-1.6073-1.7588-2.30721043.0274
Inactive043.30734.59326.16091.4977-0.3069-7.99849.32760.43930.52646.24550.6765-1.14832.95142.83040.33553.30731040.8269
Inactive01.46410.36614-6.318740 0 0 0 0 0 0 0 0 0 0 0 0 0 014.1141-3.4381-7.3489-3.26415.9377-1.29136.0792.4574-0.66819.1174-1.99613.96474.54960.21062.435814.11411040.8076
Inactive04.44950.7601-7.3061-140 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.8849-2.0187-0.9161-0.9264-2.7952-0.4328-1.6855-0.3391-0.407-2.5735-1.49410.96480.9826-2.8423-8.5884-5.8849104-2.9291
Inactive010.830117-0.034840 1 0 0 0 0 0 0 0 0 0 0 0 0 014.0286-1.145431.0664-2.11240.7218-0.0209-0.52610.88461.37251.2826-0.56811.99398.35712.3512.86214.02861043.366
Inactive04-0.1819-7.0263-5.6511-1.9334-3.7135-3.6978-5.8053-1.5642.065-2.2268-16.5881-0.3846-7.6272-6.6085-1.2608-0.1819104-0.8667
Inactive044.42848.60874.2844.04556.64827.16785.820915.600711.20528.55338.08613.78917.55046.08934.2134.42841045.3451
Inactive04-8.88941.8737-2.22351.16232.8957-10.7195-1.00881.46140.00462.21452.95272.1393-0.7247-1.0202-1.027-8.8894104-1.7136
Inactive04.95490.4507-3.3961440 0 0 0 0 0 0 0 0 0 0 0 0 0 0-9.4968-2.1527.83886.24711.14156.3871.65253.75036.13644.7998-8.8061-4.1072-2.40111.93952.6284-9.4968100.10.3228-6.7797240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.503
Inactive04-3.13693.33310.47570.23633.6413-1.1851.67973.84655.91537.55739.92998.6054-0.21813.92783.1089-3.1369104-2.15
Inactive04.95490.3773-4.36122.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-3.63430.7143-0.22365.48595.25581.75083.14210.64220.72592.48834.3837-0.00872.52846.69730.8788-3.6343104-0.2141
Inactive043.91723.01557.19690.74161.21654.60025.20565.944310.54471.99850.9756-0.07680.67112.53342.09523.9172104.95490.7847.50.279640 0 0 0 0 0 0 0 0 0 0 0 0 0 05.9565
Inactive045.8298-0.67512.41520.54165.239410.767-0.54651.59181.19133.81416.22981.75781.56111.41622.80265.8298104-0.4924
Inactive04-3.3157-1.35199.8672-1.63770.76281.52990.4097-1.04661.3819-1.6627-0.25360.405-1.83081.1677-1.1253-3.3157104.0950.7713-10.2663240 0 0 0 0 0 0 0 0 0 0 0 0 0 0-8.5553
Inactive047.8599-1.29032.81650.11083.4806-1.3434-2.64223.52578.22935.90481.45342.15660.2133-0.63753.27987.8599104.95490.38052.5-0.395740 0 0 0 0 0 0 0 0 0 0 0 0 0 1-0.5909
Inactive04-0.4616-4.8308-0.9318-4.356-1.9238-0.7086-2.3682-1.3797-3.6392-1.95447.0786-5.846-0.1781-1.1608-5.1462-0.4616104-0.1454
Inactive04.95490.3247-4.0319-0.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-5.79930.54530.0785-1.5792-1.5775-0.3717-2.37460.07991.28960.8896-0.2455-11.6933-2.313-1.97130.1175-5.7993104-0.1597
Inactive04.95490.53848-1.30340 0 0 0 0 0 0 0 0 0 0 0 0 0 10.6277-3.7875-5.2525-0.92431.34540.91270.1311-0.388-1.0844-1.7767.31937.41056.141317.9007-0.5580.6277104-0.0463
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatotoxicity
External ID: CHEMBL1697797
Protocol: N/A
Comment: Journal: Curr Drug Discov Technol
Year: 2004
Volume: 1
Issue: 4
First Page: 243
Last Page: 254
DOI: 10.2174/1570163043334794

Target ChEMBL ID: CHEMBL1697861
ChEMBL Target Name: Hepatotoxicity
ChEMBL Target Type: PHENOTYPE - Target is a biological phenotype or process
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueActivity Comment
Composite Activity - Marginal=0
Composite Activity - ScoreActive
Composite Activity - Marginal=1
Composite Activity - Active=4
Composite Activity - ScoreActive
Composite Activity - Marginal=0
Composite Activity - Active=4
Composite Activity - ScoreData Not Available
Composite Activity - Active=1
Composite Activity - Marginal=1
Composite Activity - ScoreActive
Composite Activity - Marginal=1
Composite Activity - Active=3
Composite Activity - ScoreInactive
Composite Activity - Active=1
Composite Activity - Marginal=2
Composite Activity - ScoreInactive
Composite Activity - Active=0
Composite Activity - Marginal=0
Composite Activity - ScoreActive
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR001
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inactive000406.942202.372800.458305.80229.8216000QC'd by BIOMOL
Inactive00040000.78791.0771004.091704.998300QC'd by BIOMOL
Inactive0-7.37924.95490.41460.86115.540 0 0 0 0 0 0 0 0 0 01.837309.11175.53448.2389002.305104.4881-0.94911.8373QC'd by BIOMOL
Inactive0-5.17922.72020.8215-20.66392.540 0 0 0 0 0 0 0 0 0 1-6.09160-2.79660.22858.08152.5833.73547.32021.7166-5.5554-18.8865-6.0916QC'd by BIOMOL
Inactive00043.74957.22936.37145.613507.482901.69948.4113003.7495QC'd by BIOMOL
Inactive00046.36577.19537.3079001.87945.979907.4799006.3657QC'd by BIOMOL
Inhibitor14.81835.514921Partial curve; partial efficacy-4.82923.06540.9214-31.01494.5-2.20 0 0 0 0 0 0 0 0 0 0-30.42915.77728.87813.66834.2274.72228.01864.5719-4.21873.6532-13.8256-30.4291QC'd by BIOMOL
Inactive000405.78175.8939008.5995006.074406.5850QC'd by BIOMOL
Inactive0004-2.104508.25230-2.17247.221607.3601-2.8223-6.14464.4899-2.1045QC'd by BIOMOL
Inactive0-4.42924.95490.4721-18.4451.540 0 0 0 0 0 0 0 0 0 0-13.287507.01614.53755.0482005.2422-2.8732-8.90186.1541-13.2875QC'd by BIOMOL
Inactive00049.43850000.93210.52520009.489409.4385QC'd by BIOMOL
Inactive0004-1.189406.558504.48600.538104.86393.46642.4738-1.1894QC'd by BIOMOL
Inactive0-6.07924.95490.40475.50.155340 0 0 0 0 0 0 0 0 0 101.4724.5108000-2.787208.386408.06150QC'd by BIOMOL
Inactive0004000.71730.66792.56178.0704009.810508.97310QC'd by BIOMOL
Inactive00041.1339-2.329408.3935009.78267.57146.4163001.1339QC'd by BIOMOL
Inactive0-9.02924.95490.38982-12.787140 0 0 0 0 0 0 0 0 0 1-4.0609-8.98923.4212-1.75787.17160.61375.21776.7693.1957-7.1191-0.2144-4.0609QC'd by BIOMOL
Inhibitor20.931101.63441Partial curve; high efficacy-4.67924.0950.99-99.56492.069-2.10 0 0 0 0 0 0 0 0 0 0-91.68045.251107.629403.87461.2696000-20.7764-91.6804QC'd by BIOMOL
Inactive000402.320402.28163.4121.25641.61620000.22870QC'd by BIOMOL
Inactive0-4.57924.50450.7778-24.88853.540 0 0 0 0 0 0 0 0 0 0-22.82385.74268.64626.02173.77214.16569.06293.0606-1.1003-6.03351.2279-22.8238QC'd by BIOMOL
Inhibitor33.1734109.831210Single point of activity-4.47924.95490.9783-109.32610.505-30 0 0 0 0 0 0 0 0 0 0-91.5629-0.0109-1.05751.09492.26989.4465-3.45940-7.435400-91.5629QC'd by BIOMOL
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:
External ID: GRN257
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of dexamethasone (5 nM, final concentration in the well). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT).
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1W460-Activity_Score-Replicate_1W460-Curve_Description-Replicate_1W460-Fit_LogAC50-Replicate_1W460-Fit_HillSlope-Replicate_1W460-Fit_R2-Replicate_1W460-Fit_InfiniteActivity-Replicate_1W460-Fit_ZeroActivity-Replicate_1W460-Fit_CurveClass-Replicate_1W460-Excluded_Points-Replicate_1W460-Max_Response-Replicate_1W460-Activity at 0.0000036780 uM-Replicate_1W460-Activity at 0.0000082250 uM-Replicate_1W460-Activity at 0.0000183900 uM-Replicate_1W460-Activity at 0.0000514202 uM-Replicate_1W460-Activity at 0.0001158387 uM-Replicate_1W460-Activity at 0.0002261535 uM-Replicate_1W460-Activity at 0.0004949824 uM-Replicate_1W460-Activity at 0.00102 uM-Replicate_1W460-Activity at 0.00229 uM-Replicate_1W460-Activity at 0.00510 uM-Replicate_1W460-Activity at 0.011 uM-Replicate_1W460-Activity at 0.025 uM-Replicate_1W460-Activity at 0.057 uM-Replicate_1W460-Activity at 0.127 uM-Replicate_1W460-Activity at 0.284 uM-Replicate_1W460-Activity at 0.634 uM-Replicate_1W460-Activity at 1.415 uM-Replicate_1W460-Activity at 3.154 uM-Replicate_1W460-Activity at 7.040 uM-Replicate_1W460-Activity at 15.11 uM-Replicate_1W460-Activity at 27.01 uM-Replicate_1W460-Activity at 58.48 uM-Replicate_1W460-Activity at 78.95 uM-Replicate_1W460-Activity at 216.1 uM-Replicate_1W460-Activity at 765.1 uM-Replicate_1Ratio-Activity_Score-Replicate_1Ratio-Curve_Description-Replicate_1Ratio-Fit_LogAC50-Replicate_1Ratio-Fit_HillSlope-Replicate_1Ratio-Fit_R2-Replicate_1Ratio-Fit_InfiniteActivity-Replicate_1Ratio-Fit_ZeroActivity-Replicate_1Ratio-Fit_CurveClass-Replicate_1Ratio-Excluded_Points-Replicate_1Ratio-Max_Response-Replicate_1Ratio-Activity at 0.0000036780 uM-Replicate_1
Inactive04-12.097-15.4211.22518.50446.32020.846114.98991.67820.3453-2.12172.5147-17.8498-9.32760.28162.6709-12.097104-12.0519
Inconclusive0Single point of activity-4.52134.95490.372839.41940.385430 0 0 0 0 0 0 0 0 0 0 0 0 0 032.79711.95395.33912.21820.80081.884415.32420.02920.8207-21.1398-1.4369-24.04185.752217.14520.630832.79711040.9716
Inactive04-5.25290.17872.973832.766221.31856.600616.055125.63979.842634.3918-9.8497-0.1044-5.717114.7663-0.7047-5.25291046.6113
Cytotoxic23.914544.75320Partial curve; high efficacy-4.77133.06540.9397-151.36460.7993-2.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-140.15255.712-11.72013.174311.80043.9627-11.745919.69894.1037-4.89243.0574-21.16290.0911-4.4585-74.4823-140.15250Complete curve; high efficacy-4.97133.51170.8761-65.1981-0.3709-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-64.7954
Inhibitor26.8325102.2380Single point of activity-4.57134.95490.7068-122.91268.4508-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-103.83561.9814-8.2905-0.6801-2.507810.7911-7.456524.81948.5806-7.33822.7627-1.146220.661865.1802-2.288-103.83560Single point of activity-4.57134.95490.8259-97.04015.198-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-85.6797
Inactive043.352-18.3617-0.7198-1.82120.7254-2.3887-0.71138.1346-18.636610.8874-1.88711.636-16.58518.3351-18.83343.3521042.0179
Inconclusive0Complete curve; partial efficacy; poor fit-7.52131.46410.680236.20112.51.41 0 0 0 0 0 0 0 0 0 1 1 1 1 122.057130.60393.688701.975524.92820.940436.70837.549926.490437.73945.076219.601119.7132-3.264822.0571104-2.2828
Inactive043.5852-0.9953.1779-2.90782.9481-0.79636.8681-22.0598-14.2108-2.2977-16.3346-2.03172.00522.18690.90223.5852104-2.9287
Inactive04-2.74024.46784.162900.150523.553338.24690.453-5.2560.55339.8796-0.6274-4.2999023.1032-2.7402104-6.1592
Inactive0417.07540.24292.78673.44132.792-1.4151.419821.8245-2.16183.6162-18.04260.0956-1.3056-2.398512.358417.0754104-11.8022
Cytotoxic26.832542.81820Single point of activity-4.57134.95490.9428-140.4676.5416-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-123.21672.731110.1203-0.9412-0.006715.33822.152318.6872.49431.3665-0.576414.2545-2.3685-1.0992-1.3076-123.21670Partial curve; partial efficacy; poor fit-4.52130.60.588-65.2178-6.1658-2.40 0 0 0 0 0 0 0 0 0 0 0 0 0 0-51.7601
Inconclusive0Partial curve; partial efficacy-4.92131.10.711641.11172.152.20 0 0 0 0 0 0 0 0 0 0 0 0 0 040.5279-2.658815.3997-1.32051.54133.8511.1616-0.54452.66480.16530.4079-0.475322.922612.925317.4440.5279104-1.1211
Inactive045.3983-14.35172.32162.82171.398410.6583-13.337-1.73434.042716.340518.8055-0.856912.351214.0297-4.28015.3983104-15.3874
Cytotoxic26.832560.9510Single point of activity-4.57134.95490.8965-166.924610.764-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-155.4129-4.74481.248714.33939.9359-5.64392.083840.29660.993714.79787.97237.785523.56762.329620.0585-155.41290Single point of activity-4.57134.95490.72-34.1482.3048-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-30.286
Inactive04-17.9221-5.6935-9.7378-15.0242-13.45874.1955-20.9421.6642.78496.2808-1.65063.6358-21.3152-1.5804-17.7116-17.9221104-3.4006
Inactive04-16.0736-0.16670.063414.39452.22271.76036.0139-16.78778.30026.13620.2785-23.70580.041617.93561.9071-16.0736104-0.4858
Inactive00.70.515419.5726-16.145540 0 0 0 0 0 1 0 0 0 0 0 0 0 1-18.9267-14.0001-14.1391-15.825-18.1982-31.1347-5.992124.7447-16.7843-1.0696-18.5346-4.5707-4.9181-7.002213.1558-18.9267104-7.4051
Inactive04-15.437230.19180.87326.82955.19737.68435.82839.8057-1.3433-0.6271-0.7496-16.36081.435420.67980.2025-15.43721040.541
Inactive04-8.09546.20142.679-3.15441.45620.91-3.2719-6.17514.4834-9.2058-3.6067-5.2067-7.29356.5535-11.4671-8.0954104-19.5741
Inconclusive04-6.5078-13.7847-11.6608-0.2953-62.2272-22.8473-5.7475-4.5773-29.0585-18.6043-33.5711-11.69590-23.5243-23.2348-6.50780Single point of activity-4.57134.95490.701639.7004-8.651930 0 0 0 0 0 0 0 0 0 0 0 0 0 036.4575
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Hepatotoxicity
External ID: CHEMBL1697798
Protocol: N/A
Comment: Journal: Curr Drug Discov Technol
Year: 2004
Volume: 1
Issue: 4
First Page: 243
Last Page: 254
DOI: 10.2174/1570163043334794

Target ChEMBL ID: CHEMBL1697861
ChEMBL Target Name: Hepatotoxicity
ChEMBL Target Type: PHENOTYPE - Target is a biological phenotype or process
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular
Standard TypeStandard RelationStandard ValueActivity Comment
Alkaline Phosphatase Increase - Index ValueData Not Available
Alkaline Phosphatase Increase - Number of ReportsData Not Available
Alkaline Phosphatase Increase - Activity ScoreData Not Available
Alkaline Phosphatase Increase - Activity ScoreInactive
Alkaline Phosphatase Increase - Index Value=0
Alkaline Phosphatase Increase - Number of Reports<4
Alkaline Phosphatase Increase - Activity ScoreInactive
Alkaline Phosphatase Increase - Index Value=1.2
Alkaline Phosphatase Increase - Number of Reports>=4
Alkaline Phosphatase Increase - Activity ScoreMarginally Active
Alkaline Phosphatase Increase - Index Value=3.1
Alkaline Phosphatase Increase - Number of Reports>=4
Alkaline Phosphatase Increase - Activity ScoreInactive
Alkaline Phosphatase Increase - Index Value=2.3
Alkaline Phosphatase Increase - Number of Reports>=4
Alkaline Phosphatase Increase - Activity ScoreActive
Alkaline Phosphatase Increase - Number of Reports>=4
Alkaline Phosphatase Increase - Index Value=6.3
Alkaline Phosphatase Increase - Activity ScoreInactive
Alkaline Phosphatase Increase - Index Value=0.5
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: MDR002
Protocol: The HeLa derivative cell line, KB-3-1, and its colchicine-selected, P-gp-overexpressing subline, KB-8-5-11 were maintained in DMEM with 10% FCS and Pen/Strep with glutamine at 37 degree C in 5% CO2. For KB-8-5-11 cells, colchicine was added to the medium at a concentration of 100 ng/mL. HEK-293 cells transfected with empty vector (pcDNA) or vector containing human ABCB1 (MDR-19) or ABCG2 (R-5) have been described previously (Robey, Lin, Qiu, Chan & Bates, 2011) and were maintained in EMEM supplemented with 10% FCS, Pen/Strep and glutamine with 2 mg/ml G418 to select for the expression of the transporter. Cultures were confirmed to be free of mycoplasma infection using the MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD). For the screen, assay medium was identical to culture medium except for KB-8-5-11 where colchicine was excluded from the medium.

All cell lines were plated into 1536-well plates at 500 cells/well in 5 uL media. Compounds were then pinned in dose-response using a 1536-head pin tool (Kalypsis, San Diego, CA) and plates were incubated at 37 degree C in 5% CO2 for an additional 72 h. CellTiter-Glo reagent (Promega) was dispensed into the wells, incubated for 5 min and luminescence was read on a ViewLux instrument (Perkin-Elmer). Cytotoxic compounds were defined as those that yielded a curve class of -1.1, -1.2, -2.1, -2.2, -2.3, or -2.4, a maximum response of >50% and an AC50 of < 10 uM. Cherry-picked hits from screening analysis were tested with both the KB pair of cell lines, and the pcDNA (empty vector control) and MDR-19 (P-gp overexpressing) pair were tested, in the absence and presence of tariquidar.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000073700 uMActivity at 0.0000311978 uMActivity at 0.0000755538 uMActivity at 0.0001700784 uMActivity at 0.0003537877 uMActivity at 0.0007609388 uMActivity at 0.00133 uMActivity at 0.00267 uMActivity at 0.00634 uMActivity at 0.00855 uMActivity at 0.017 uMActivity at 0.041 uMActivity at 0.071 uMActivity at 0.179 uMActivity at 0.354 uMActivity at 0.663 uMActivity at 1.576 uMActivity at 1.933 uMActivity at 5.110 uMActivity at 9.286 uMActivity at 17.35 uMActivity at 44.46 uMActivity at 93.38 uMActivity at 162.7 uMCompound QC
Inhibitor4.109535.955421Complete curve; partial efficacy-5.38621.47870.9847-33.45542.5-1.20 0 0 0 0 0 0-32.46282.18335.970600-5.6126-25.295-32.4628QC'd by Axon Medchem
Inhibitor14.58134.657110Partial curve; partial efficacy; poor fit-4.83622.33320.9403-32.15712.5-2.40 0 0 0 0 0 0-29.71430007.41155.8195-6.9018-29.7143QC'd by Tocris
Inactive0-4.83621.86170.9256-16.65942.540 0 0 0 0 0 0-14.71612.62120.581.02516.28291.7864-3.3449-14.7161QC'd by Glixx
Inhibitor1.63666.161564Complete curve; partial efficacy-5.78622.72020.9997-65.81160.3499-1.20 0 0 0 0 0 0-66.50140000-37.9408-64.7373-66.5014QC'd by Glixx
Inactive0-4.63621.96730.7584-23.667-2.467140 0 0 0 0 0 0-19.3058-0.694-0.3893-3.2758-10.1148-2.3842-5.3061-19.3058QC'd by SIGMA
Inactive0-4.78623.06541-20.0675040 0 0 0 0 0 0-19.222900000-2.9492-19.2229QC'd by Axon Medchem
Inhibitor10.322547.836221Partial curve; partial efficacy-4.98621.88510.9724-41.83626-2.20 0 0 0 0 0 0-38.7819.20936.095507.71415.1385-14.8631-38.781QC'd by MedChem Express
Inactive00046.01782.42486.41361.896906.213206.0178QC'd by Tocris
Inhibitor29.092960.09310Single point of activity-4.53624.95491-60.03460.0584-30 0 0 0 0 0 0-54.4164000000-54.4164QC'd by Tocris
Inactive0004-6.543200000-1.4393-6.5432QC'd by Tocris
Inhibitor16.360136.851110Partial curve; partial efficacy; poor fit-4.78621.010.8986-32.35114.5-2.40 0 0 0 0 0 0-23.62598.789708.696100-7.2303-23.6259QC'd by Tocris
Inactive00049.2406001.75143.496707.9269.2406QC'd by Glixx
Inhibitor9.233.715210Partial curve; partial efficacy; poor fit-5.03621.41630.9706-30.21523.5-2.40 0 0 0 0 0 0-27.26265.31472.675106.30420-12.9935-27.2626QC'd by Tocris
Inhibitor16.360152.695221Partial curve; partial efficacy-4.78621.28760.9602-49.04213.653-2.20 0 0 0 0 0 0-37.79029.1493005.18520-13.7877-37.7902QC'd by Tocris
Inactive0-4.78624.44950.9565-27.1196340 1 0 0 0 0 0-26.76640-80.85495.97525.378600.9575-26.7664QC'd by Tocris
Inhibitor0.580574.818526Complete curve; partial efficacy-6.23623.67720.9839-72.75452.064-1.20 0 0 0 0 0 0-64.73751.50932.14072.7381-9.5317-70.5587-81.6221-64.7375QC'd by MedChem Express
Inhibitor18.356499.324110Single point of activity-4.73623.62720.9917-97.78141.5427-30 0 0 0 0 0 0-94.201708.64420-1.04460-6.3447-94.2017QC'd by Tocris
Inhibitor29.092985.830210Single point of activity-4.53624.95490.9979-84.3311.4991-30 0 0 0 0 0 0-76.60620.5645002.14332.14953.4024-76.6062QC'd by MedChem Express
Inhibitor12.995349.172121Partial curve; partial efficacy-4.88622.25260.9678-45.67253.4996-2.20 0 0 0 0 0 0-42.17617.83150.28501.26966.3138-12.2728-42.1761QC'd by Tocris
Inactive0-4.68621.88510.8683-38.0965-12.016740 0 0 0 0 0 0-33.4065-7.5139-13.5025-14.684-16.035-8.8732-16.7676-33.4065QC'd by Selleck
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: GRV193
Protocol: Tox21 Assay Protocol Summary:

The GR-bla HeLa cells were dispensed at 1500 cells/5 ul/well in 1536-well black wall/clear bottom plates using a Multidrop Combi (ThermoFisher Scientific, Waltham, MA) dispenser. After the assay plates were incubated at a 37 C/5% CO2 incubator for 4 hours, 23 nL of compounds dissolved in DMSO, positive controls or DMSO only was transferred to the assay plate by a pintool station (Kalypsys, San Diego, CA), followed by addition of 1 uL of dexamethasone (5 nM, final concentration in the well). The plates were incubated at 37 C for 18 hours. After 1 uL of LiveBLAzerTM B/G FRET substrate was added using a Flying Reagent Dispenser (Aurora Discovery, San Diego, CA), the plates were incubated at room temperature (RT) for 2 hours, and fluorescence intensity was measured by an Envision plate reader (PerkinElmer, Shelton, CT). After measurement of bla assay, 3 ul CellTiter-Glo (Promega, Madison, WI) was added to measure the cytotoxicity and the plates were then incubated at RT for 30 min. The luminescence was measured using a ViewLux (Perkin Elmer) plate reader.
Comment: Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
Phenotype-Replicate_1Potency-Replicate_1Efficacy-Replicate_1Analysis Comment-Replicate_1Activity_Score-Replicate_1Curve_Description-Replicate_1Fit_LogAC50-Replicate_1Fit_HillSlope-Replicate_1Fit_R2-Replicate_1Fit_InfiniteActivity-Replicate_1Fit_ZeroActivity-Replicate_1Fit_CurveClass-Replicate_1Excluded_Points-Replicate_1Max_Response-Replicate_1Activity at 0.0000036780 uM-Replicate_1Activity at 0.0000082250 uM-Replicate_1Activity at 0.0000183900 uM-Replicate_1Activity at 0.0000514202 uM-Replicate_1Activity at 0.0001156673 uM-Replicate_1Activity at 0.0002261535 uM-Replicate_1Activity at 0.0004949824 uM-Replicate_1Activity at 0.00102 uM-Replicate_1Activity at 0.00229 uM-Replicate_1Activity at 0.00510 uM-Replicate_1Activity at 0.011 uM-Replicate_1Activity at 0.025 uM-Replicate_1Activity at 0.057 uM-Replicate_1Activity at 0.127 uM-Replicate_1Activity at 0.284 uM-Replicate_1Activity at 0.634 uM-Replicate_1Activity at 1.415 uM-Replicate_1Activity at 3.154 uM-Replicate_1Activity at 7.040 uM-Replicate_1Activity at 15.11 uM-Replicate_1Activity at 27.01 uM-Replicate_1Activity at 58.48 uM-Replicate_1Activity at 78.95 uM-Replicate_1Activity at 216.1 uM-Replicate_1Activity at 765.1 uM-Replicate_1Compound QC-Replicate_1Phenotype-Replicate_2Potency-Replicate_2Efficacy-Replicate_2Analysis Comment-Replicate_2Activity_Score-Replicate_2Curve_Description-Replicate_2Fit_LogAC50-Replicate_2Fit_HillSlope-Replicate_2Fit_R2-Replicate_2Fit_InfiniteActivity-Replicate_2
Inactive04-8.9896-7.3975-6.7113-14.8241-4.5178-1.517512.264-8.1607-13.49270.92690.0472-1.09210.2383-2.6378-1.9489-8.9896QC'd by SequoiaCytotoxic0.006727.901520Complete curve; partial efficacy; poor fit-8.17134.95490.4115-26.6818
Inactive04-12.8644-12.4335-6.4744-20.0821-10.89713.6433-6.8703-5.7214-9.84543.7236-7.371-2.7049-10.4097-16.8792-5.8495-12.8644QC'd by FLUKAInactive0
Inactive00.60.6935-5.705513.540 0 0 0 0 0 0 0 0 0 0 0 0 0 0-2.93149.184113.869-0.63448.33090.23784.4977-4.6175-6.73290.5376-2.5323-8.0879-5.8972-4.0555-7.5668-2.9314QC'd by FLUKACytotoxic47.715650.274420Partial curve; partial efficacy; poor fit-4.32130.30.4501-54.3952
Inactive0412.0884-2.3949-3.4828-3.133815.632524.520517.03-4.6009-4.4756-1.6879.12462.7279-2.11843.193-0.18912.0884QC'd by BIOMOLInconclusive1.068269.039710Partial curve; partial efficacy; poor fit-5.97130.20.438955.7277
Cytotoxic26.832573.745320Single point of activity-4.57134.95490.8323-69.69384.0515-30 0 0 0 0 0 0 0 0 0 0 0 0 0 0-61.368517.6007-1.759413.0949-3.274312.563612.30281.95770.648-6.95350.28381.5448-0.0522-1.42575.7042-61.3685QC'd by BIOMOLCytotoxic21.313893.273741Partial curve; high efficacy-4.67132.90230.9235-86.9043
Inactive046.7909-1.31027.7383-4.547-2.65212.1059-2.4181-1.10118.09747.2420.3477-5.05879.40029.3931-0.87996.7909QC'd by BIOMOLInactive0
Inactive041.4423-3.99322.77927.1221-0.8837-8.95352.295-0.51041.37322.285720.59571.5207-5.3744.2397-11.91461.4423QC'd by BIOMOLInactive0
Inactive00.60.3367-9.79324.540 0 0 0 0 0 0 0 0 0 0 0 0 0 12.02261.3465-0.45472.410510.291411.99868.0638-8.1616.00951.6819-2.0122-2.01511.6093-6.3684-6.20422.0226QC'd by BIOMOLInactive02.47290.378538.7776
Inactive0415.2343-1.80842.058715.92577.90848.0244-2.30815.36692.48331.03819.9575-3.366-5.2227-2.2446-0.160715.2343QC'd by BIOMOLInactive0
Inactive047.9538-1.872810.9648-1.09872.6071-1.078614.35211.0497-1.76951.8577-2.7126-2.4267-0.2948-1.380911.52387.9538QC'd by BIOMOLInconclusive18.995953.670810Partial curve; partial efficacy; poor fit-4.72132.40640.570554.7236
Inactive04.95490.518517.50.289140 0 0 0 0 0 0 0 0 0 0 0 0 0 013.283514.4715-2.8018-2.2504-1.854-1.0751.91726.8822-1.1544-5.5924-0.0354-3.34427.78934.034525.595213.2835QC'd by BIOMOLInactive0
Inactive049.45185.1439-10.9187-3.6004-4.60710.015617.848513.801-6.53560.5436-3.981315.85290.99558.7778-0.51489.4518QC'd by BIOMOLInconclusive0.169342.502710Single point of activity-6.77133.92950.653739.4606
Inactive041.8471-10.88334.52062.79765.23563.9098-5.1881-2.0961-0.0954-3.919-3.2093-1.8064-33.7228-4.1242-0.88821.8471QC'd by BIOMOLInactive04.95490.31142.5
Inactive044.8349-4.63776.5338-3.86720.3182-6.07670.8186-2.79026.0128-0.779714.731111.52557.4133-0.9249-2.93594.8349QC'd by BIOMOLInactive04.95490.371213.3777
Inactive04-4.067912.1355-8.423722.677520.0333.0761-4.23854.78041.17568.42751.9834-7.49172.3009-2.1910.399-4.0679QC'd by BIOMOLInconclusive0.016923.312910Complete curve; partial efficacy; poor fit-7.77134.95490.334218.2886
Inactive042.05745.26574.3417-5.6188-2.5518-0.73413.2906-1.1924-0.81874.4295-6.552710.0188-0.8658-4.17642.45482.0574QC'd by BIOMOLInactive0
Inactive048.5616-2.0682-0.46498.21222.20687.6990.2449-0.087712.19887.0464-0.3008-1.4858-2.93310.76220.39078.5616QC'd by BIOMOLInactive0
Cytotoxic6.00796.604783Complete curve; high efficacy-5.22134.95490.9827-93.96262.6422-1.10 0 0 0 0 0 0 0 0 0 0 0 0 0 0-96.07621.3064-6.14065.13090.1256-0.83290.3014-0.60629.61044.55867.1299-0.84948.1454-69.6407-92.7982-96.0762QC'd by BIOMOLCytotoxic5.353889.607684Complete curve; high efficacy-5.27134.95490.9148-95.5166
Inactive04-3.2987-4.8177-8.49767.47813.7599.2959-2.2766-1.27941.7611-5.167216.38672.699710.28948.2038-9.5775-3.2987QC'd by BIOMOLInconclusive0.030119.213610Complete curve; partial efficacy; poor fit-7.52134.95490.332612.8869
Inactive048.7339-1.21470.07750.0749-2.3291-0.54618.96933.3015-2.1752-15.4981-13.43471.2297-0.91132.62215.99288.7339QC'd by BIOMOLInactive0
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:N/A
External ID: PLD386
Protocol: Assay Protocol Summary:

HepG2 cells are dispensed at 900 cells/3 uL/well into Collagen I-coated 1536-well black-wall/clear-bottom assay plates (Greiner Bio-One, Monroe, NC) using the Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). The assay plates are incubated at 37 C for 4 hours to allow the cell attachment. 3 uL of 1:500 LipidTOX Red dye is added using the dispenser, and then 23 nL compounds are added via a Wako Pintool station (Wako Automation, San Diego, CA). Amiodarone, a known PLD inducer, was used as a positive control and DMSO was used as a negative control. The assay plates were then incubated at 37 C for 24 hours.

For fixations, 4 uL of 8% paraformaldehyde fixative solution containing 10 ug/mL Hoechst 33342 in Dulbecco's phosphate-buffered saline (DPBS) is added using a Kalypsys washer/dispenser (Kalypsys, San Diego, CA, USA). After incubation at room temperature for 30 min, the assay plates are washed once with DPBS using a Kalypsys washer/dispenser. The assay plates are then sealed and stored at 4 C before imaging. The fluorescence intensities (595 nm excitation, 615 nm emission for LipidTOX; 352 nm excitation, 461 nm emission for Hoechst 33342) are measured using an ImageXpress Micro Widefield High Content Screening System (Molecular Devices, Sunnyvale, CA, USA) with a 20x Plan Fluor objective. Images are acquired for one site in each well and analyzed with the MetaXpress software (Molecular Devices) using the Transfluor module. Several algorithmic outputs, such as pit count per well, pit count per cell, pit integrated intensity per well, and pit integrated intensity per cell, are used for quantitative image analysis for PLD.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00559 uMActivity at 0.012 uMActivity at 0.025 uMActivity at 0.039 uMActivity at 0.059 uMActivity at 0.137 uMActivity at 0.153 uMActivity at 0.306 uMActivity at 0.612 uMActivity at 0.710 uMActivity at 1.532 uMActivity at 3.148 uMActivity at 4.894 uMActivity at 7.662 uMActivity at 15.53 uMActivity at 19.04 uMActivity at 38.30 uMActivity at 69.89 uMActivity at 78.45 uMActivity at 150.9 uMActivity at 192.2 uMCompound QC
Inactive040.52250.9197-0.2148-3.0798-0.7670.5225QC'd by NCI
Inactive04.95490.8575-2.5047240 0 0 0 0-1.01231.96521.94551.9624-3.7539-1.0123QC'd by NCI
Inactive03.92950.83390.0205640 0 0 0 0-0.59373.8164-1.23290.78590.4134-0.5937QC'd by NCI
Inactive040.409-0.922-0.3836-0.40790.28520.409QC'd by SigmaAldrich
Inactive01.210.57212.5-3.682440 0 0 0 02.3849-1.4022.82760.22324.62172.3849QC'd by NCI
Inactive044.1808-1.330312.1123-1.67094.93474.1808QC'd by NCI
Inactive04-0.1837-0.95772.373-1.54381.4476-0.1837QC'd by NCI
Inactive040.46912.01460.25580.34690.4350.4691QC'd by NCI
Inactive04.50450.94036-0.886640 0 0 0 05.8940.1078-1.9889-1.3913-0.60335.894QC'd by NCI
Activator28.183821.270410Partial curve; partial efficacy; poor fit-4.554.95490.994720.5-0.77042.40 0 0 0 016.7877-1.4632-0.6573-0.2313-1.475416.7877QC'd by Labotest
Inactive04-0.1246-1.73481.1946-0.6236-2.6757-0.1246QC'd by NCI
Inactive04-1.78780.0388-2.7225-2.2048-3.4121-1.7878QC'd by NCI
Inactive04.95490.7197-1.20362.540 0 0 0 0-0.44512.63960.68823.5768-2.253-0.4451QC'd by NCI
Activator8.912523.358910Partial curve; partial efficacy; poor fit-5.053.06540.991522-1.35892.40 0 0 0 021.82270.1626-2.3824-1.40577.419521.8227QC'd by NCI
Inactive041.0997-1.7227-0.835.0E-4-0.03191.0997QC'd by NCI
Inactive044.0416-0.1081-0.36380.1442-0.67394.0416QC'd by NCI
Inactive01.06410.9939-6.19520.540 0 0 0 11.19570.784-0.0956-1.6108-4.32931.1957QC'd by NCI
Inactive04-0.2978-0.07670.61.2943-0.2232-0.2978QC'd by Chembridge
Inactive041.282-0.3951-1.4501-0.0311-2.36261.282QC'd by NCI
Inactive02.40640.31175-240 0 0 0 07.0020.90276.95040.35115.08377.002QC'd by NCI
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:824 靶标:glucocorticoid receptor [Homo sapiens]
External ID: GRA646
Protocol: Please refer to other AIDs 720691, 720687, 720685, 720678 and 720681, for detailed assay protocols.
Comment: This summary is written for the purposes of summarizing the compound activities from the project combining the results from both the GR agonist mode assay (AID 720691) and auto fluorescence counter screens (AIDs 720687, 720685, 720678 and 720681). For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Potency and efficacy were used for determining relative score. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 5 and 30 determined by phenotype.

Disclaimer:

Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods. Alternative analysis methods and interpretations of the data are available at EPA (http://actor.epa.gov) and NTP (http://tools.niehs.nih.gov/cebs3/ui/).

Activity SummaryRatio ActivityRatio Potency (uM)Ratio Efficacy (%)530 nm Activity530 nm Potency (uM)530 nm Efficacy (%)460 nm Activity460 nm Potency (uM)460 nm Efficacy (%)Blue (460 nm) auto fluorescence outcomeSample Source
inconclusiveinconclusive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inconclusiveactive agonist26.2133798280.63773882active antagonist23.36269936-80.71273442active antagonist26.21337982-33.67998135inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inconclusive agonist0inconclusive agonist0inactiveSigmaAldrich
inconclusiveinconclusive agonist25.01773299170.756549active antagonist26.21337982-71.55109769inconclusive antagonist26.83246391-39.31724907inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inconclusiveactive agonist14.2449376949.76333982active antagonist13.44808836-78.84104162inconclusive antagonist13.44808836-40.31184202inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich
inactiveinactive0inactive0inactive0inactiveSigmaAldrich